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ABSTRACT 
Chronic neuropathic pain (NeP) is a complex condition that is commonly seen in primary care 
and is often refractory to current recommended treatments. Novel approaches to pain 
management are increasingly being studied to address this issue including the use of cannabis, a 
plant that has been used medicinally for thousands of years. The aim of this project was to 
review the current literature to determine if medical marijuana can be authorized safely by 
primary care providers (PCPs) to treat NeP in adults. Rational prescribing guidelines were used 
as the foundation for determining safety. Background knowledge of pain, chronic pain, 
neuropathic pain, analgesia, the history of medical marijuana, marijuana licensing, pharmacology 
of cannabis, including what is known about the efficacy on NeP, medical marijuana and society, 
nurse practitioner prescriptive authority and safe prescribing practices formed the basis of this 
review. The 12 studies utilized in this review do not provide enough data to support the safe use 
of medical marijuana for NeP in adults. It may be considered after guideline recommended 
prescription treatments have failed in specific clients taking into account the limitations of the 
evidence and associated risks . For those PCPs who are considering authorizing dried cannabis 
for their clients recommendations for practice will be discussed. Areas for future research and 
limitations of the review will also be acknowledged. 
Keywords: cannabis, medical marijuana, neuropathic pain, nurse practitioner, safe prescribing 
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INTRODUCTION 
The dried plant form of cannabis is a preparation from the Cannabis sativa species and is 
acknowledged for its psychoactive, medicinal, and analgesic properties dating back thousands of 
years (ElSohly & Slade, 2005; Greenwell, 2012). The therapeutic potential of cannabis has been 
historically supported by anecdotal reports and more recently by experimental animal and human 
studies (Fontelles & Garcia, 2008; Greenwell, 2012). It is being used for a variety of conditions 
including chemotherapy induced nausea and vomiting, anxiety, depression, migraine, 
osteoporosis, glaucoma, spasticity, wasting syndrome, multiple sclerosis, spinal cord injury, 
epilepsy, anorexia nervosa, sleep disorders and pain syndromes (Health Canada, 2013a). The 
extensive preclinical research has revealed analgesic properties of both exogenous and 
endogenous cannabinoids on the endocannabinoid system; this has prompted an increase in 
dedicated clinical studies to evaluate the safety and efficacy of dried cannabis. This increase also 
comes from a recognized need to develop new strategies for pain conditions that respond poorly 
or are refractory to current treatment regimens and public pressure (Abrams et al., 2007a; 
Finnerup, Sindrup, & Jensen, 2010; Wilsey et al., 2013). 
One condition commonly seen in primary care that often responds poorly to currently 
recommended treatments is neuropathic pain (NeP) (Fitmerup et al. , 2010; Gilron et al. , 2006). 
Neuropathic pain results as a complication of diabetes, alcoholism, herpes zoster, HIV, 
amputation, multiple sclerosis, chemotherapy, spinal cord injury and facial nerve problems 
(Canadian Neuropathy Association, 2013). The synthetic cannabinoid nabilone and dried 
cannabis derivative Sativex have demonstrated some efficacy for the treatment ofNeP in clinical 
trials and are available by prescription in Canada (Karst et al. , 201 0; Lynch & Campbell, 2011; 
and Martin-Sanchez, Furukawa, Taylor & Martin, 2009). 
Current indications include for multiple sclerosis and cancer induced pain, nausea and 
vomiting (Government of Canada, 20 12a) though off-label use of nabilone is not uncommon. 
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Dried cannabis is not legally approved for use as a therapeutic agent in Canada but the 
Marihuana for Medical Purposes Regulations legislation permits the limited sale of cannabis for 
medicinal purposes (Health Canada, 20 13b ). Individuals are given a medical document by their 
physician that authorizes a license for legal access to buy and use the dried cannabis plant for a 
specific medical condition. However, physicians have expressed concern with the lack of 
literature and evidence to provide guidance on how to authorize this licensure safely (College of 
Family Physicians of Canada [CFPC] , 2014). Nurse practitioners (NPs), as primary care 
providers (PCPs ), are also concerned regarding the lack of evidence for dried medical marijuana 
authorization, because they have recently become another group of PCPs that have been granted 
authority by federal legislation to authorize its use, with final regulation resting with the 
provinces. The medico-legal implications of utilizing this substance in practice, when ambiguity 
surrounds its appropriate use and safety, is a concern for PCPs. 
Rational clinical decision-making incorporates the principles of safe prescribing using a 
standardized method that evaluates the risks, benefits, potential complications and drug 
interactions associated with the use of a medication (College of Physicians and Surgeons of 
British Columbia [CPSBC], 2014). An authorization for medical marijuana is not a true 
prescription because it does not include all the key elements of traditional controlled drugs and 
substance (CDS) prescriptions including the use of a numbered, personalized PCP duplicate 
prescription pad that has the date, patient name and address, name of drug, strength, dose, route, 
quantity, directions for use and practitioner signature (College of Pharmacists of British 
Columbia, 201 0) . Further, CDS prescriptions are void if not filled within five days of date 
3 
written (College of Pharmacists ofBritish Columbia, 2011). However, though dried cannabis is 
not regulated by Health Canada, PCPs are expected to use the same standards when assessing the 
suitability and safety of a prescription medication for a client when authorizing medical 
marijuana (CPSBC, 2014). Thus, the aim of this project is to review the current literature to 
determine if dried cannabis can be authorized safely by PCPs to treat NeP in adults. The World 
Health Organization (WHO) published a guideline, Guide to Good Prescribing: A Practice 
Manual (de Vries et al., 1994) that identifies six key steps in the process of rational prescribing 
(see Appendix A). All of the steps are important to follow but for the purpose of this project, step 
three of the guideline will be highlighted as it focuses on the suitability and safety of prescribed 
medications. The efficacy in meeting the therapeutic objective, the drug's adverse and toxic 
effects, contraindications, drug-interactions, proper dosing and method of delivery, client mental 
status, presence of comorbidities and cost to the client are evaluated in this step (de Vries et al., 
1994). 
This review begins with an in depth discussion of the pathophysiology of pain, chronic pain, 
neuropathic pain, the endocannabinoid system, the pharmacology of cannabis, medical marijuana 
licensing, NP prescriptive authority legislation in Canada, and the guidelines and principles that 
define rational prescribing. The methods section will detail how the literature search was 
completed. The findings will provide an analysis of the studies presenting key themes for further 
examination. The discussion section will provide a synthesis of the current evidence from the 
literature that will be followed by recommendations for practice and future research. 
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CHAPTER! 
Background 
Neuropathic pain is a complex condition that responds sub-optimally to the current 
recommended treatments . Thus, the objective of this review is to determine if dried cannabis can 
be authorized safely by PCPs to treat NeP in adults. This section will provide the reader with the 
necessary background information on neuropathic pain, dried medical marijuana, and the 
principles of safe prescribing. 
Pathology of Pain 
Pain is a subjective sensory symptom that is invisible and difficult to measure. It also has 
physical, psychological and emotional components (Baron, Binder & Wasner, 2010). It occurs as 
a result of a variety of pathological conditions and is generally divided into two types: 
nociceptive and neuropathic (King et al., 2013). Nociceptive pain, which has both visceral and 
somatic varieties, is typically associated with a direct response to tissue damage from noxious 
stimuli that happens with injury, inflammation or cancer. Neuropathic pain occurs with damage 
to the neural tissue of the central nervous system (CNS) and peripheral nervous system (PNS) 
(Rang et al. , 2012). 
At the microscopic level, peripheral sensory neurons, called polymodal nociceptors, in 
visceral and somatic tissue respond to noxious chemical, mechanical, or thermal stimuli by 
activating sodium channels in the cell membrane. Sodium channels generate electrical impulses 
that are transmitted along afferent nerve fibers from the PNS to the CNS where the stimuli are 
received (Rang et al. , 2012). Areas of the CNS involved in pain processing include parts of the 
thalamus, somatosensory cortex, periaqueductal gray, basal ganglia, cerebellum, amygdala, and 
hippocampus (Aggarwal, 2013). Pain is inhibited when these impulses leave the brain and travel 
along descending efferent pathways (Rang et al. , 2012). 
Chemical mediators are also released that act on these peripheral sensory neurons to induce 
pain and include bradykinin, protons, adenosine triphosphate (A TP), histamine and transient 
receptor potential channels (TRP) (Rang et al. , 2012). In addition, bradykinins release 
prostaglandins that enhance pain production by increasing nociceptor pain sensitivity. 
Acute pain stimulation is typically self-limiting as it disappears when the original insult has 
resolved. However, prolonged insult to these pain receptors can result in a continuation of pain 
signalling past the normal point of termination, resulting in the initiation of a chronic 
pathological state process that produces chronic pain. 
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Chronic pain. Chronic pain that is not due to cancer or cancer related conditions. It is 
defined as pain that lasts beyond the duration of time that the original injury would normally take 
to heal; this is generally longer than three to six months (Canadian Psychological Association, 
2014). Many clinical pain states fall under this category of chronic non-cancer pain and may 
include phantom limb pain, fibromyalgia and neuropathic pain. Chronic pain is a major issue in 
Canada and results in a reduced quality of life and productivity. It is estimated that 15% to 19% 
of Canadians over the age of 15 have chronic non-cancer pain, with 11.4% to 13.3% reporting a 
negative effect on their daily activities (Reitsma et al., 2011). One type of chronic pain that 
differs in its pathophysiology when compared to nociceptive chronic pain is neuropathic pain. 
Neuropathic pain. Neuropathic pain (NeP) is a type of pain that is induced by several 
pathological mechanisms that result from neuronal damage. Inflammatory mediators are released 
when a nerve is injured with resulting peripheral and central sensitization. Overexpression and 
hyper-excitability ofthe voltage gated sodium channels leads to over firing of nerve impulses in 
injured and neighbouring non-injured afferent pain pathways (Baronet al. , 2010). CNS immune 
modulators are also released during inflammation and contribute to the sustainment of pain 
without any external stimulus. Further, descending efferent nerve pathways are responsible for 
pain inhibition but lesions on these nerves directly impair their ability to inhibit the pain signal 
(Baronet al. , 2010). 
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The sympathetic nervous system (SNS) also plays a role in NeP. Sympathetic neurons can 
grow into the injured dorsal root neurons. Sympathetic fibers also grow into the injured dermis. 
This results in both an increased number and activity of calcium ion gated channels sensitive to 
circulating catecholamines (Gilron et al. , 2006). This pathology produces allodynia, which is, the 
initiation of pain without a noxious stimulus (Gilron et al. , 2006). Medications that target these 
calcium ion channels, such as the antiepileptic gabapentin, can be effective for relieving NeP. 
NeP is generally differentiated on the basis of pathology involving the PNS or CNS (Moulin 
et al. , 2007). Causes of central NeP include post-stroke pain, multiple sclerosis, fibromyalgia, 
and spinal cord injury (Moulin et al., 2007). Causes of peripheral NeP include diabetic 
neuropathy, post-herpetic neuralgia, HIV distal sensory polyneuropathy, amputation and 
chemotherapy (Canadian Neuropathy Association, 2013; Moulin et al. , 2007). Symptoms ofNeP 
are divided into spontaneous pain and stimulus-evoked pain (Moulin et al. , 2007). The burning, 
shooting and lancing pain with a feeling of tightness is characteristic of spontaneous pain 
whereas the symptoms of allodynia and hyperalgesia are associated with stimulus-evoked pain 
(Moulin at al., 2007). There are specific validated screening tools including the "Douleur 
Neuropathique en 4 questions" (DN4) (Bouhassira et al. , 2005) and the Leeds Assessment of 
Neuropathic Symptoms and Signs (LANSS) (Bennett, 2001) that help to diagnose NeP in order 
to tailor treatment. 
Individuals differ in their response to treatments and this is partially the result of the 
underlying complexity ofNeP and individual genetic variability (Baronet al. , 2010). New 
research is uncovering more details explaining the neural mechanisms of pain. As a result, new 
targets for pain management and analgesia are being developed (Rang et al. , 2012). 
Analgesia 
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Analgesia is the inability to feel pain and is a result of endogenous opioids and the 
neurotransmitters serotonin and norepinephrine (Bauldoff et al. , 2011 ). An analgesic is a class of 
drug that relieves pain without blocking nerve impulse conduction or sensory function. This 
includes two drug classes, the opioids and the non-steroidal anti-inflammatory medications 
(NSAIDs) (Rang et al. , 2012). There are other classes of drugs, including antiepileptics and 
antidepressants, which also exhibit analgesic qualities but work differently from opioids and 
NSAIDs. Acute pain responds more favourably to those medications that exert their action on 
normal pain pathway receptors seen with nociceptive pain. NSAIDs are effective for mild and 
moderate nociceptive pain arising from muscles and vessels seen in arthritis, bursitis, toothaches, 
painful menses, and bone cancer (Rang et al. , 2012). They exert their effects by decreasing the 
production of prostaglandins in the PNS and inhibiting the release of prostaglandins from the 
spinal cord. Prostaglandins sensitize nociceptors to inflammatory mediators such as bradykinin 
(Rang et al., 2012). Acetaminophen exhibits a similar pharmacological activity to NSAIDs but 
with fewer anti-inflammatory effects (Bauldoff et al., 2011) 
Opioids are a group of substances that target the opioid receptors located on neurons of the 
PNS and CNS (Rang et al., 2012). Their action results in the inhibition of nociceptive impulse 
transmission through the dorsal hom of the spinal cord, the suppression of neurotransmitter 
release presynaptically and response postsynaptically, and the release of serotonin from the 
descending inhibitory pathways (Rang et al., 2012). They are generally quite effective for the 
management of acute nociceptive pain and for some types of chronic pain (Rang et al., 20 12). 
8 
Opioids are commonly prescribed for NeP but have shown only a small or modest benefit 
(National Opioid Use Guidelines Group [NOUGG], 2010). They are third line agents in the 
Canadian neuropathic pain guidelines (Moulin et al., 2007). Those with NeP are thus likely 
prescribed higher opioid doses to improve efficacy; however, higher doses of opioids are 
associated with higher rates of adverse effects, dependence and abuse (NOUGG, 2010). A 
balance between effective pain management and preventing harms with opioid use is a challenge 
for PCPs. As a result, alternative therapies are being sought that target other receptors (NOUGG, 
2010). 
Medications that are indicated for non-pain conditions that target the PNS and CNS have 
shown some efficacy for chronic pain like NeP. Tricyclic antidepressants (TCAs) act centrally to 
inhibit noradrenaline reuptake whereas the antidepressant venlafaxine inhibits both serotonin and 
norepinephrine reuptake (Rang et al., 2012). Antiepileptic drugs, gabapentin and pregabalin, 
reduce neurotransmitter release by inhibiting calcium channel function; their action is enhanced 
in the presence of damaged sensory neurons (Rang et al., 2012). These classes of drugs are first 
and second line agents in the national and international NeP pain treatment guidelines (Attal et 
al., 2010; Moulin et al., 2007). The complexity ofNeP is being increasingly studied and new 
research into the role of the endocannabinoid system for analgesia has revealed some interesting 
findings. 
Endocannabinoid System 
The endocannabinoid system is a lipid signalling system with two main receptors, 
cannabinoid one (CB 1) and two (CB2). These are activated by the endocannabinoid mediators, 
anandamide and 2-arachidonoyl glycerol (2-AG) (Rang et al. , 2012). This system is found in all 
vertebrates and has important regulatory functions. 
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CB 1 receptors are found throughout the PNS and CNS encompassing the areas of the brain 
responsible for memory, coordination, appetite, body temperature, psychological "reward", and 
in central and peripheral pain pathways including peripheral nociceptors (Rang et al. , 2012).They 
are also found in adipocytes, leukocytes, the spleen, heart, lungs, gastrointestinal tract, kidney, 
bladder, reproductive organs, skeletal muscle, bone, joints, and skin (Health Canada, 2013a). 
They are involved in many processes including stimulation of the immune system (Greineisen & 
Turner, 2010), lipogenesis (Rang et al. , 2012), and reproductive system suppression (Brown & 
Dobs, 2002). They are also involved in the pathogenesis of nonalcoholic fatty liver disease and 
progression of liver fibrosis in chronic liver disease (Mallat & Lotersztajn, 2008). 
CB2 receptors are expressed in the tissues and cells of the immune system including 
leukocytes, the spleen, tonsils, thymus, liver, bone and some nerve cells (Rang et al., 2012). The 
activation of these receptors results in immune suppression (Greineisen & Turner, 2010), 
atherosclerosis (Rang et al. , 2012), and the regulation of pain (Fontelles & Garcia, 2008). 
Components of the cannabis plant and its derivatives exert their effect on the 
endocannabinoid system receptors, key therapeutic targets in the management ofNeP. 
Medical Marijuana 
History of use. Dried marijuana has been used for over a thousand years for medicinal 
purposes; however, its therapeutic value has only been supported by anecdotal evidence and less 
rigorously designed scientific studies (Greenwell, 2012). In 1997, the United States Institute of 
Medicine (IOM) was tasked to analyze the existing research on the potential health benefits of 
dried cannabis and its isolated cannabinoids (Joy, Watson & Benson, 1999). These early studies 
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identified cannabis and its derivatives as potential therapeutic agents for several neurological 
conditions. From this preliminary data recommendations were made to conduct further research 
using rigorous clinical trials. 
Canadians have had access to dried medical marijuana since 1999 through an exemption 
created under section 56 ofthe Controlled Drugs and Substances Act (Government of Canada, 
2014). In 2000, the Ontario Court of Appeal (Regina. vs Parker) ruled that an individual has the 
right, as set out under the Canadian Chart of Rights and Freedoms, to reasonable access to a 
legal source of marijuana for medical purposes (Government of Canada, 20 12a). Thus, in 2001, 
the Marihuana Medical Access Regulations (MMAR) were established (Government of Canada, 
2001). Medical cannabis was approved for use in clients who had significant nausea, anorexia, 
weight loss, persistent muscle spasms, seizures, severe pain cancer, AIDS, multiple sclerosis, 
spinal cord injury, epilepsy, and severe arthritis (Government of Canada, 2001). However, with 
the increasing numbers of Canadians accessing marijuana under the MMAR, there have been 
stakeholder concerns over how the MMAR creates barriers to access. There were concerns that 
the current system threatens public safety because of unregulated growing operations. Thus, in 
March of2014, significant amendments were made. The new Marihuana/or Medical Purposes 
Regulations (MMPR) were created with the following objectives: to produce quality controlled 
dried marijuana, to require only licensed producers with an unencumbered process of medical 
marijuana licensing, and to only permit direct sale of marijuana to individuals in possession of a 
license (Government of Canada, 2012a). Health Canada claims the aim ofthe regulation is to 
treat medical marijuana like any other controlled substance for medical purposes and for licensed 
producers to be subject to regulatory requirements including proper security, packaging, 
labelling, shipping, distribution, record keeping and reporting (Government of Canada, 2012a). 
The intention is also to reduce the risk for and incidence of diversion among distributors. 
However, a document for medical marijuana does not follow the same standards as a CDS 
prescription as previously discussed (College of Pharmacists of British Columbia, 2011 ). 
Further, this increase in regulatory oversight will likely increase the cost of dried cannabis to 
consumers which may deter some from obtaining a license and instead use illegal sources of 
cannabis that are not quality controlled (Government of Canada, 2012a). 
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Medical marijuana license. Health Canada does not regulate or approve of medical 
marijuana; thus, a medical marijuana document given to a client from a PCP is not a prescription 
but an authorization that provides the patient with a license to possess dried cannabis for medical 
purposes. However, despite the lack of pharmaceutical regulation and intrinsic safeguards seen 
with traditional prescriptions of medications, it is still the responsibility of the PCP to 
demonstrate proper evaluation of clients for the risks, benefits, potential complications and drug 
interactions of cannabis, in addition to screening for risks of abuse and addiction (College of 
Physicians and Surgeons of British Columbia [CPSBC], 2014). The current limited research 
available surrounding the safety of medical marijuana has made it difficult for PCPs to embrace 
it as a therapeutic option, particularly with the ambiguity surrounding efficacy, dosing and 
frequency. 
Composition. Marijuana, or Cannabis sativa, is a hemp plant that grows in temperate and 
tropical climates. It contains over 400 distinct chemical compounds (ElSohly & Slade, 2005). 
The leaves and flowering tops contain over 70 exogenous phytocannabinoids (Aggarwal, 2013; 
ElSohly & Slade, 2005). These act on the CB 1 and CB2 receptors and cause effects similar to the 
endogenous mediators, anandamide and 2-AG. The most studied andabundant cannabinoid in 
cannabis is delta-9-tetrahydrocannabinol (THC) and is responsible for most of the physical and 
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psychotropic effects (Rang et al., 2012). The highest concentration ofTHC is found in the 
mature flowering heads and it is this part that is cultivated and used to produce the desired 
therapeutic and recreational psychoactive properties (Health Canada, 2013a). Currently, Health 
Canada provides dried marijuana with a THC concentration of 12.5±2% and less than 0.5% of 
the other cannabinoids including cannabidiol (CBD), cannabigerol (CBG), and cannabichromene 
(CBC) (Health Canada, 2013a). It is estimated that illegal forms of marijuana contain THC 
concentrations in the range of 1% to 30% with an average of 10% (Health Canada, 2013a). One 
of the main objectives ofthe revised MMPR was to establish quality controlled marijuana with 
known cannabinoid concentrations by licensed producers (Government of Canada, 2012a). 
Knowing the THC concentration of a given strain contributes to safety by providing a consistent 
dose. Health Canada (20 14) also provides an updated list of authorized licensed producers for 
access by the public. 
Clinical pharmacology. THC is a partial agonist and cannabidiol (CBD) an antagonist at the 
CB 1 and CB2 receptors (Izzo et al., 2009). Cannabidiol also targets calcium ion channels; 5-
lipoxygenase and phospholipase A2 enzymes; and the tryptophan, 5-HT1A, adenosine, glycine, 
and opioid receptors which produces the anti-inflammatory, analgesic, anti-nausea, antipsychotic 
and anxiolytic effects (Izzo et al., 2009). It also demonstrates anti-convulsant activity and 
induces hepatic drug metabolism (Rang et al., 2012). Preliminary research has shown that CBD 
appears to mitigate THC's psychoactive effects but enhance its analgesic effect. An important 
relationship to consider when prescribing different strains of cannabis since the therapeutic 
effects will vary somewhat. They produce analgesic effects through their action on both 
ascending and descending pain pathways where they suppress calcium ion conduction that is 
responsible for nerve firing and transmission (Aggarwal, 2013). 
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The pharmacological effects of cannabis are numerous. Age, immune status, concurrent use 
of other medications and substances, method of delivery, dose, previous cannabis experience, 
and composition of cannabis plant used influence the effects experienced by a given individual 
(Hunault et al. , 2009). Many of the effects of cannabis occur biphasically with lower doses 
causing effects that are opposite to effects seen with higher doses (Mechoulam & Parker, 2013); 
this is a characteristic shared with opioids (NOUGG, 2010). Further, some studies have shown 
cannabis to have a narrow therapeutic window for analgesia with hyperalgesia occurring at high 
doses (Wallace et al. , 2007; Wilsey et al., 2008). These characteristics stress the importance of 
careful titration to avoid adverse effects. 
Physiological effects measured in animal and human studies include pharmacological 
activity on most body systems. CNS effects include the impairment of short-term memory and 
learning, subjective feelings of confidence and heightened creativity, impairment of motor 
coordination, catalepsy, hypothermia, analgesia, antiemetic action and increased appetite (Rang 
et al. , 20 12). Peripheral effects include tachycardia, vasodilatation, reduction of intraocular 
pressure and bronchodilation (Rang et al., 2012). 
Pharmacokinetics. There are several routes for cannabis administration. Each route has a 
distinct mode of absorption and time to onset of activity (Aggarwal, 2013). The plant material 
can be ingested orally, absorbed through the lungs via smoking or inhalation of vapors, applied 
topically, or absorbed through the oral mucosa (Health Canada, 2013a). 
Smoking. The onset of action of smoked cannabis occurs within seconds to minutes with 
peak effects reached at 30 minutes and duration of two to three hours (Rang et al., 2012). 
Smoking cannabis results in a higher plasma level of cannabinoids and a shorter duration of 
action compared to oral administration. This rapid entry into CNS contributes to the intense 
pleasure experienced by some users. This rapid euphoria also contributes to its abuse potential 
(Huestis, 2007). Factors that impact levels of absorption of THC and the other cannabinoids 
include the source of the plant material, composition of the cigarette, and the efficiency and 
method of smoking by the person such as the depth of inhalation, puff duration and breath hold 
(Health Canada, 2013a). THC bioavailability with smoking ranges from 23±16% (Lindgren et 
al., 1981) in experienced users and 10±7% in occasional users (Grotenhermen, 2003). Also, as 
the marijuana cigarette shortens in length the concentration increases (Carter, Weydt, Kyashna-
Tocha, & Abrams, 2004). 
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Vaporization. Vaporization is an alternative method of drug inhalation. Cannabis is heated to 
a temperature between 180 and 200 and vapors are inhaled. It is theorized that these cannabinoid 
vapors form below the temperature of combustion where toxic compounds, such as tar, are 
released, making this a safer route of administration (Abrams et al., 2007b; Wilsey et al., 2013). 
However, studies have shown that carbon monoxide, tar, and other carcinogenic compounds 
including polycyclic aromatic hydrocarbons are released and absorbed in the lungs, though in 
smaller amounts compared to the smoking route (Health Canada, 2013a). This has led to the 
belief that the risks of respiratory disease and cancer are lessened with this method. However, 
there is not enough data to confirm this finding. The onset of action, peak plasma levels, and 
subjective effects of vaporized cannabis are similar to the smoked form in clinical studies 
(Abrams et al., 2007b; Wilsey et al. , 2013). 
Oral ingestion. Cannabis can be consumed orally in butters, oils, brownies, teas, and 
cookies. There is variability of the amount ofTHC absorbed when ingested orally because of 
individual differences in rates of absorption, metabolism and excretion (Huestis, 2007). Peak 
plasma levels are reached between one to six hours (Grotenhermen, 2003) and duration of action 
is between five to eight hours (Huestis, 2007) though cognitive function can be impaired for up 
to 24 hours in some cases (CFPC, 2014). The oral form results in lower bioavailability and 
plasma levels compared to the smoked form because of the first past hepatic effect 
(Grotenhermen, 2003); one study showed only a range of 6±3% (Ohlsson et al., 1980). 
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Other forms of cannabis administration includes oromucosal, rectal and topical but will not 
be discussed further in this review as the current literature reviewed discusses the smoking, 
vapor and oral ingestion routes only, as these are the most common routes of ingestion for dried 
cannabis. 
Distribution. THC is absorbed by the fatty tissues, heart, lungs, liver and brain (Health 
Canada, 2013a). The blood brain barrier slows the crossing ofTHC that results in a delay 
between peak plasma levels and psychoactive effects (Health Canada, 2013a). This effect on the 
brain is a concern for users who titrate their dose of cannabis based on a subjective "high" that 
occurs after peak plasma levels have been reached. This has the potential to put the client at risk 
for more serious adverse effects. THC accumulates and is retained in fatty tissue, which may 
explain why adverse effects are observed in organs that contain this type of tissue, including the 
reproductive organs and the brain (Huestis, 2007). 
Metabolism and excretion. THC and cannabidiol are metabolized in the liver to active 
metabolites by the xenobiotic cytochrome P450 enzymes, CYP2C9 and CYP3A4 (Watanabe et 
al. , 2007). With oral cannabis, metabolism by the liver results in the formation of higher levels of 
the psychoactive metabolite, 11-hydroxy-THC, which results in increased sedation compared to 
the inhalation route (Grotenhermen, 2002). 
More than 65% of cannabis is excreted in the feces and 20% is excreted by the kidneys with 
no differences between the sexes (Wallet al. , 1983). Excretion also occurs through the hair, 
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sweat and oral fluids (Huestis, 2007). Cannabis is highly lipophilic; thus, complete elimination 
from the body occurs slowly over several days due to its slow release from body fat (Aggarwal, 
2013). The terminal half-life of dried cannabis varied among studies due to variations in lab test 
measurement sensitivities in the measurement (Huestis, 2007). One study that measured urinary 
excreted cannabis metabolite determined the half-life to be three to four days (Johansson & 
Halldin, 1989). 
Adverse effects. Reported adverse effects from cannabis are based mainly on studies of 
recreational users; there is a lack of data with non-recreational cannabis users. The short-term 
effects in clinical trials demonstrate a peak effect at 30 minutes that lasts for several hours 
(Grotenhermen, 2003). The time frame considered long term has been mainly based on studies 
evaluating subjects who have used marijuana for several years; it is unclear at what point long-
term effects start to appear initially (Gordan, Conley & Gordon, 2013). 
Physical effects. Short-term adverse effects include tachycardia, bronchodilation (Tashkin, 
2013 ), arteritis, hypotension, and multifocal vasoconstriction. Multifocal vasoconstriction may 
lead to reversible ischemic stroke (Wolff et al., 2011 ). Long-term adverse effects include 
hyperemesis, reproductive and immune system alteration, and increased rates of chronic 
bronchitis and lung infections. Long-term chronic heavy users of cannabis demonstrate lung 
changes that include mutagenic changes, suppressed activity of alveolar macrophages, and 
increased airway resistance induced by airway inflammation (Tashkin, 2013). An association 
between cannabis use and lung cancer was recently confirmed in data collected from a 40 year 
cohort study, even accounting for baseline tobacco and alcohol use, pre-existing respiratory 
conditions and socioeconomic status (Callaghan, Allebeck, & Sidorchuk, 2013). Tolerance, 
physical dependence and psychological addiction occur in both infrequent and heavy users of 
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cannabis. This occurs as a result of CB 1 receptor down regulation and desensitization (Health 
Canada, 2013a). Withdrawal symptoms include depressed mood, anger, aggression, cravings, 
headache, restlessness, anxiety, irritability and decreased appetite (Budney, Hughes, Moore & 
Vandrey, 2004). Symptoms begin within one to two days of discontinuation with peak symptoms 
occurring between two and six days. Resolution occurs within one to two weeks (Budney et al., 
2004). 
Cognitive effects. Short-term effects on cognition include impaired learning, sedation, 
memory, attention, judgment, concentration, executive function, and psychomotor coordination 
(Rang et al. , 2012; Volkow, 2014). Impaired driving and increased risk for motor vehicle 
accidents have been associated with cannabis use (Calabria et al. , 2010). Long-term effects 
include impaired fetal neurocognitive development, impaired brain development, lowered IQ in 
frequent users during adolescence, and addiction (Volkow, 2014). One prospective study found 
that persistent cannabis users who started in adolescence had impaired neuropsychological 
functioning even after one year of abstinence; a finding not found in persistent users who had 
started in adulthood (Meier et al. , 2012). 
Psychological effects. Short-term effects include anxiety, paranoia and psychosis (Volkow, 
2014). Long-term effects include diminished life satisfaction and achievement, chronic 
psychosis, depression and addiction (Volkow, Baler, Comptom & Weiss, 2014). Evidence has 
shown cannabis use to be a trigger for earlier age onset of schizophrenia and bipolar disorders in 
genetically susceptible individuals (Volkow et al., 2014). 
Addiction. Up to 9% of those who experiment with cannabis will become addicted 
(Anthony, 2006) based on the criteria for cannabis use disorder recognized by the DSM-V 
(American Psychological Association, 2013). Higher ratesare seen in those who initiate cannabis 
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use in adolescence withone out of six becoming addicted (Anthony, 2006) and 25% to 50% 
becoming addicted who smoke it daily (Hall & Degenhardt, 2009). In Canada, statistics from 
2012 showed a lifetime prevalence rate for cannabis abuse or dependence of6.8% (Statistics 
Canada, 2013). The presence of withdrawal symptoms makes cessation more difficult and results 
in higher relapse rates (Volkow et al., 2014). In 2009 to 2010, statistics from Ontario showed 
38.2% of men and women who went to Ontario treatment centres identified cannabis dependence 
as their primary reason for admission (Rotondi & Rush, 2012). It is the most commonly used 
illegal substance in Canada with the most recent statistics reporting a prevalence rate of 10.2% in 
Canadians over the age of 15 (Health Canada, 2012). 
Toxicity . The cannabis dose that induces intoxication is variable among users though doses 
greater than 5 grams per day are associated with greater risk for dependence and adverse effects 
(Health Canada, 2007). Toxic effects include tachycardia, hyperemesis, hypotension, psychosis, 
anxiety, and impaired motor coordination, memory and concentration (Weinstein & Gorelick, 
2011 ). Most effects are self-limiting and mild though there have been two reported cases of death 
directly attributable to cardiovascular complications caused by smoking cannabis in two young 
adults (Hartung, Kauferstein, Ritz-Timme & Daldrup, 2014). 
Drug-interactions. THC and cannabidiol are metabolized in the liver by the cytochrome 
P450 CYP2C9 and CYP3A4 enzymes. These enzymes are also involved in the metabolism of 
other drugs. Limited studies have shown THC to inhibit the metabolism of haloperidol and 
induce the metabolism of phenytoin, indinavir and nelfinavir (Mozayani & Raymon, 2011). 
Medications that inhibit THC metabolism include fluoxetine, nicotine and tricyclic 
antidepressants (Mozayani & Raymon, 2011 ). Cannabis also interacts with substances that act on 
the central nervous system including alcohol and lorazepam; increased sedation is observed 
when these are combined with marijuana (Canadian Pharmacists Association, 2014a). 
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Contraindications. Dried cannabis use is contraindicated or cautiously used in populations 
that are vulnerable to the adverse effects discussed in the previous text (Health Canada, 20 13a). 
The brain remains in an active state of development into young adulthood (Lebel & Beaulieu, 
2011) and is more vulnerable to environmental insults (Volkow et al., 2014). THC affects neural 
connections in the brain that manifests as impaired learning, memory, self-awareness, alertness, 
and inhibitory control (Volkow et al. , 2014). Thus, those under 25 should not be prescribed 
cannabis. Further, it is advisable to avoid use in those with severe cardio-respiratory, liver, renal, 
severe mental illness including schizophrenia or psychosis, and pregnant or breastfeeding 
(Health Canada, 2013a). Caution or avoidance is also warranted if prescribing for clients with 
history of active or remote substance abuse, mania, depression, or on concurrent anti-psychotic 
or sedative-hypnotic medications (Health Canada, 2013a). 
Dosing. The optimal dose of medical marijuana should improve pain relief and function 
while causing minimal euphoria or cognitive impairment (CFPC, 2014). However, therapeutic 
dosing of cannabis is complex due to several factors : the pharmacological complexity of 
cannabis, the inconsistent and variable concentration of active ingredients due to conditions of 
plant growth, harvesting practices, heterogeneity ofTHC concentrations used in clinical studies, 
individual genetic variability in the physiological response to the drug, individual variability with 
method used for delivery, and varying pharmacokinetics among the different ingestion methods 
(Carteret al., 2004). Health Canada has made recommendations for the daily dose of cannabis 
based on the results from surveys in peer-reviewed literature. In any form of ingestion, with a 
THC concentration of 12.5± 1.5%, the daily dose should be limited to between 1 and 3 grams of 
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dried plant (Health Canada, 2013a). More recent guidelines released by the CFPC (2014) advise 
a daily inhaled dose of 100 mg to 700mg of a THC concentration up to 9%. This dose is similar 
to that found in one retrospective study done in the Netherlands (N=5540) where the average 
daily dose of cannabis used for therapy, of varying potencies, was 0.68 grams per day 
(Hazekamp & Heerdink, 2013).This narrower daily dose suggested by CFPC will likely 
contribute to a better safety profile and lower incidence of adverse effects although the dosing is 
not as refined as prescription oral cannabinoids. 
Frequency of dosing differs between methods of ingestion. Health Canada (2013a) advises 
users to wait a few minutes between puffs of smoked cannabis. The evidence from clinical 
studies demonstrates a shorter time period between puffs at an average of 45 to 55 seconds 
though most of these subjects were not cannabis naive. For a client who has never used cannabis 
or is trying a new strain, the lowest concentration of THC available is recommended as a single 
slow inhaled puff. Then, the individual should wait four hours to assess the efficacy (CFPC, 
2014). For oral ingestion, the user should wait at least 60 minutes between bites of oral ingestion 
to determine strength of effect due to the slower achievement to peak plasma levels (Carter et al, 
2004). 
Cost. Medical marijuana is not covered under any provincial or federal prescription drug 
plan so the entire cost is left to the client. The new MMPR anticipates an increase in cost from 
the current $1.80 to $5.00 per gram to $7.60 per gram this year with a further increase to $8 .80 
per gram (Government of Canada, 2012a). For clients who require treatment long term, this is a 
significant expense. For example, a client that uses one gram per day would expect to spend from 
$1825.00 to $2774.00 per year; this is a conservative estimate. This is in comparison to nabilone, 
which costs $2.73 per lmg tab (London Drugs Pharmacist, personal communication, November 
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10, 2014). If a person takes the standard dose (one to two tabs twice daily) this amounts to 
$10.92 per day or $3985.80 per year not including the pharmacy dispensing fee. However, many 
provincial drug plans cover the partial cost of this medication; for example, in BC Pharmacare 
pays for $1.67 of the cost of each lmg nabilone tab (British Columbia Ministry of Health, 2014). 
Sativex costs $662.24 for a 30 ml bottle (London Drugs Pharmacist, personal communication, 
November 10, 2014) or $2.21 per spray. The normal dose is four to eight sprays per day, the cost 
of which equals approximately $8.84 to $17.68 per day and this medication is not covered by 
provincial drug plans though it may be covered by private insurance. Thus, the use of medical 
marijuana and other cannabinoids is limited to those who can afford it. 
Prescription Cannabinoids 
Health Canada regulates and approves the use of two types of cannabinoid medications 
available by prescription. Nabilone is an oral synthetic cannabinoid used for nausea and vomiting 
associated with cancer therapy and Sativex is an oromucosal spray made from cannabis plant 
extracts used for multiple sclerosis and cancer pain (Government of Canada, 2012a). Both of 
these medications have standardized concentrations and dosing that follow traditional medical 
prescribing protocols with better efficacy and safety profiles than dried cannabis. Sativex, for 
instance, combines two chemical extracts, THC and cannabidiol, from the plant in a fixed ratio 
ensuring a precise concentration for a metered, recordable dose (Brown john & Ashton, 20 12). 
Both of these medications have adverse effect profiles and contraindications similar to the 
natural plant fonn (Canadian Pham1acists Association, 2009; 2014b). 
Medical Marijuana and Society 
Marijuana remains a controversial substance due to several societal and clinical concerns. It 
is an illegal substance often involved in diversion (Government of Canada, 2012a) and its use 
22 
can lead to abuse and addiction (Lucas, 2012; Volkow, 2014). There is also a prevailing view 
called the "gateway drug" theory that its use leads one to use more dangerous illicit substances 
(Lucas, 2012; Volkow et al., 2014). Indeed, epidemiological (Agrawal, Neale, Prescott & 
Kendler, 2004) and animal (Panlilio et al., 2013) studies have confirmed that THC primes the 
brain for addiction and enhances the responses to other drugs in susceptible individuals. 
However, the alternative theory is that people who are already more susceptible to drug use start 
with marijuana because of ease of accessibility and their social interactions with other drug users 
increases the likelihood of trying other drugs (Volkow et al., 2014). Further, reports of its 
therapeutic value have been mainly based on personal testimony and not on the results of 
rigorous scientific research trials (Bostwick, 2012). The CFPC (2014) report a keen interest in 
medical marijuana by patients often accompanied by less interest in the available evidence. The 
two dominant Canadian political parties are divided in their view of the legalization of 
marijuana. The Liberal Party of Canada is in favour of the decriminalization and legalization of 
medical marijuana whereas the Conservative Party opposes the decriminalization (Kennedy, 
2014). A Canadian opinion poll by Ipsos Reid (N = 3000) found 37.3% in favour of marijuana 
legalization and 33.4% in favour of less punitive penalties for possessing small amounts, 
preferring fines instead of a criminal record (Kennedy, 2014). It is clear that a significant 
majority of Canadians in this poll do not support legalization nor the relaxed penalties for 
possessiOn. 
Current legislation and public opinion has likely contributed to pressure for researchers to 
gain support and funding to conduct scientific trials evaluating the therapeutic value of dried 
cannabis. Further, PCPs are taught to base clinical decision-making on evidence-based 
information. The lack of scientific evidence supporting the therapeutic value of dried cannabis, 
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the ambiguity around appropriate dosing, and the lack of regulatory oversight put PCPs in an 
uncomfortable position. Further, synthetic cannabinoids are already available and regulated by 
Health Canada. They also have a greater body of evidence for efficacy with lower rates of both 
adverse effects and addiction risk (CFPC, 2014) They are approved for use in a few conditions 
including multiple sclerosis and cancer related pain, nausea and vomiting. Off-label use for other 
conditions, however, is common (Government ofCanada, 2012a). Finally, high rates of abuse 
and recreational use, supported by the current evidence, makes it difficult for the PCP to ensure 
that the prescribed marijuana will be used only for its intended therapeutic purposes. 
Guidelines on Cannabis for Neuropathic Pain 
The CFPC released preliminary guidelines, Authorizing Dried Cannabis for Chronic Pain or 
Anxiety, in September 2014 to assist prescribers by providing suggested approaches for the 
authorization of dried cannabis for medical purposes. This literature review evolved in 
September 2013 out of a lack of clinical guidelines on the objective but has included all relevant 
and current literature up to January 2014 with periodic evaluation for new studies. Thus, the 
results at the initiation of this review are based on a paucity of clinical guidelines at that period in 
time. New guidelines have been recently released and there will be further comment on those 
recommendations . 
The College ofPhysicians and Surgeons ofBritish Columbia (CPSBC) released a brief 
position and guidance on what should be assessed and documented when authorizing a medical 
marijuana license. Most notably, it was suggested that trials of unsuccessful therapies be 
documented. It was also suggested that the dose and frequency of marijuana use be specifically 
stated and that a one year expiration date be included as well (CPSBC, 2014). 
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Prior to the release of these two guidelines the Canadian Pain Society released the 
Pharmacological Management of Chronic Neuropathic Pain - Consensus statement and 
Guidelines from the Canadian Pain Society with the recommendation that cannabinoids be 
considered fourth line treatment in the management ofNeP when other treatments have failed or 
are not available (Moulin et al., 2007). There were only two studies used to support this 
recommendation and they utilized the synthetic and medicinal extract forms of cannabinoids 
available by prescription. In 2010, the European Federation ofNeurological Sciences (EFNS) 
Task Force issued guidelines for NeP treatment with the recommendation to use synthetic 
cannabinoids as second or third line treatment for central pain in multiple sclerosis. There was 
also one recommendation to use the dried plant form of smoked cannabis for HIV -associated 
polyneuropathy (Attal et al., 201 0). 
Nurse Practitioners and Prescriptive Authority 
The introduction of the NP as a PCP has increased access to primary care for many 
Canadians (Canadian Nurses Association, 2008). Patients commonly present with acute and 
chronic pain in primary care; this is the most common reason for analgesic and or narcotic 
prescriptions (Gerhardt, 2004). As PCPs, NPs are educated in pain and pain management. This 
includes both non-pharmacologic and pharmacologic treatments and moreover, the judicious use 
of CDS. In 2012, the federal Controlled Drugs and Substances Act included NPs as health care 
providers with the authorization to prescribe CDS, though final regulation, standards, and 
processes rest with the provinces and territories (Government of Canada, 20 12b ). In jurisdictions 
where NPs controlled substance prescriptive authority has not yet been completed, a physician's 
signature is required. The College of Registered Nurses of British Columbia (CRNBC) is 
currently working with the Minister of Health to establish policy that will ensure public safety 
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for NPs who will be prescribing CDS. The first phase of CDS prescribing legislation will not 
include medical marijuana; CRNBC (2014a) states that after NPs have had experience with 
prescribing CDS will they consider what needs to be in place for medical marijuana 
authorization. Safe prescribing for NPs requires a strong foundation of education and policy 
support. Safety in medication prescribing is paramount to protect the public and avoid ineffective 
or harmful treatments, the prolongation or worsening of illness, needless suffering and excessive 
health care system costs (de Vries et al., 1994). A license to authorize medical marijuana 
warrants the same consideration for safety that is given to the writing of a traditional 
prescription. And, the use of guidelines, such as the one developed by the WHO, will help 
clinicians do this. 
Medication Prescription Safety 
The practice of rational prescribing seeks to avoid ineffective and unsafe treatments, illness 
exacerbation or prolongation, higher costs, and prescriber vulnerability to patient, colleague or 
industry pressure (de Vries et al., 1994). The WHO's Guide to Good Prescribing: A Practice 
Manual (de Vries et al., 1994) was developed to help the prescriber avoid the above with 
identification of six key steps for HCPs to follow in the process of rational prescribing (see 
Appendix A). Step three considers the suitability and safety of the drug for a particular client 
with evaluation of the efficacy on the therapeutic objective, adverse effects, contraindications, 
drug-interactions, proper dosing, appropriate method of delivery or formulation, client's mental 
status and cost (Devries et al., 1994). It is this step that formed the basis ofthis literature review. 
The evaluation of the evidence concerning the suitability and safety of medical marijuana was 
highlighted in this review, although the author acknowledges that all six steps are essential to 
rational prescribing. 
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Several factors influenced the development of this review including: federal government 
legislation granting access to medical marijuana, patient requests for it, anecdotal evidence and 
limited clinical studies that indicate it may relieve NeP, potential future legislation granting NPs 
to authorize its use, and a lack of clinical guidelines for how to use it safely. There are legitimate 
concerns surrounding the health risks associated with the use of dried cannabis since most people 
will opt for the smoked method of ingestion. The objective of this is to determine if medical 
marijuana can be authorized safely by PCPs to treat NeP in adults. 
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CHAPTER2 
Methods 
A literature review was carried out to determine if dried cannabis can be authorized safely by 
PCPs to treat NeP in adults. The methodological process for reviewing the literature was 
completed in four stages. 
Stage One: Identification of Issue and Search Strategy 
Stage one started with identification of key terms related to the objective. The dried cannabis 
plant is the compound available through the Marihuana for Medical Purposes Regulations 
(Government of Canada, 2013). Therefore, the initial terms used in the literature search included 
cannabis and medical marijuana in combination with the term neuropathic pain on Google and 
Google scholar. These terms were further used in health-related research databases to determine 
MeSH headings when applicable. The databases used to conduct the searches included those 
with relevancy to medicine, nursing, clinical studies, and Canadian content though the search 
was expanded to international sources because of the limited local and national information. The 
Cochrane Database of Systematic Reviews, EBM reviews, Database of Abstracts of Reviews of 
Effects, ACP Journal Club, Cochrane Central Register of Controlled Trials, CINAHL, Medline 
ovid, Medline with full text, Pubmed, Psychinfo, Biomedical reference collection, and 
Longwoods were searched. An online search was completed using government and professional 
websites such as Health Canada, the Government of Canada, the National Guidelines 
Clearinghouse, the Canadian Medical Association, and the American Psychiatric Association. In 
addition, journals associated with the Canadian Pain Society, International Association for the 
Study of Pain and the American Pain Society were also explored. Figure lB details the initial 
search that resulted in 360 articles for further evaluation using an inclusion and exclusion criteria 
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(see Table 1). A ten year time frame was utilized to obtain the most current and relevant 
evidence as the initial cursory search revealed no observational or experimental studies dated 
earlier than 2004. 
Table 1: Inclusion and Exclusion Criteria 
Inclusion Criteria • quantitative and qualitative human studies that evaluated the 
efficacy of the cannabis plant on neuropathic pain 
• any method of cannabis used including smoking, vaporization, 
oral ingestion, topical, rectal or oromucosal ingestion 
•literature published between 2004 and up to January 2014 
• Canadian literature was the main focus of the search due to the 
applicability of the literature to Canadian NP practice but the 
search was expanded to American, European, and Asian sources 
in an effort to ensure all key research data applicable to cannabis 
on neuropathic pain was included 
• English language literature or sources that were translated into 
English 
Exclusion Criteria • studies that used animals as subjects as data from these is not 
easily transferred to humans or to clinical practice (Karst et al. , 
2010) 
• studies that evaluated other forms of pain or disability 
• synthetic or prescription medicinal extracts of cannabis such as 
dronabinol, nabilone or nabiximols 
Stage Two: Focused Search 
Stage two of the search strategy involved the use of Refworks as a citation manager for 
collecting the articles. Figure 1 details the narrowing down of articles through the removal of 
duplicates, evaluation of the titles, abstracts and full text systematically until key articles were 
revealed. The references of these key articles identified by the initial search were reviewed for 
additional literature; 12 studies met the inclusion and exclusion criteria and were found to be 
relevant to the objective. 
Stage Three: Study Quality Analysis 
Stage three involved a detailed analysis of the chosen articles for quality of evidence using a 
modified checklist tool by Downs and Black (1998) (see Table C1). It gives a score out of28 and 
is based on evaluation of the reporting, internal validity, external validity, and power of 
randomized and non-randomized studies. 
Figure 1: Literature Search Flow Chart 
Initial search: 360 articles 
Hand search of 63 
references screen = 9 
Criteria = 12 studies 
Title screen: 360 arti cles 
Duplicates screen = 156 
Literature = 55 
) I Title screen = 204 excluded 
Duplicates removed = 86 
Abstract screen = 7 excluded 
There were 12 clinical studies that consisted ofboth experimental and observational 
quantitative research designs. The experimental studies included seven randomized controlled 
trials (RCTs), an open-label pilot study, and an open-label clinical trial. The observational 
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studies included a sub-analysis of a RCT, a case series, and a cross-sectional questionnaire study. 
The inclusion of both experimental and observational studies was deliberate so the strengths of 
each type of study would be complementary to the other in order to provide a synthesis of 
evidence for application in clinical practice. 
Stage Four: Identification of Key Themes 
Stage four involved a detailed evaluation of these 12 studies with identification of key 
themes related to the research question. Themes identified in the literature included: examination 
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of the efficacy of dried cannabis on N eP compared to current guideline recommended 
medications, the relationship between adverse effects, drug-interactions and contraindications to 
specific client groups, dried cannabis dosing and appropriate method of delivery. The following 
findings section will provide a critical analysis of the quality of evidence presented in each study. 
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CHAPTER3 
Findings 
The following section will provide a critical analysis of the research findings, organized by 
the key themes and will include a specific focus on step three of the WHO Guide to Good 
Prescribing: A Practice Manual (de Vries et al. , 1994). The themes identified include: the 
efficacy of cannabis in comparison to currently recommended treatments for NeP; the 
relationship of adverse effects, drug interactions and contraindications associated with specific 
client groups, and the recommended dose and method of delivery of dried cannabis. Table C 1 
details the evaluation of the studies using the "Checklist for Measuring Quality " tool by Downs 
& Black (1998) to identify the internal and external validity and the reliability of the studies' 
results. The quality ofthe experimental studies ranged from 22 to 27 out of28; one open label 
trial rated the lowest at 13 out of 28. The observational studies scores ranged from 18 to 21. 
Studies with scores below 14 are considered poor quality, 15 to 19 as fair quality, and greater 
than 20 as good quality. Thus, the methodological quality of the studies in this review are 
acknowledged to have flaws that will be discussed and analyzed further. 
Efficacy of Cannabis on Neuropathic Pain Compared to Current Treatments 
When selecting a medication for a client it is important to know how effective it is in terms 
of the therapeutic objective (de Vries et al. , 1994). In this case, the literature was evaluated to 
determine the efficacy of cannabis as a treatment for NeP in comparison to current guideline 
recommended medications. All 12 studies reported improvement in NeP after the use of dried 
cannabis. Seven of the RCTs showed statistically significant pain relief when compared to the 
placebo with five of these studies reporting a clinically significant 30% reduction in pain from 
the baseline (see Table C2). Three of the clinical studies acknowledged the difficulty with 
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blinding due to the psychoactive effects of cannabis (Corey-Bloom et al. , 2010; Ellis et al., 2007; 
Wilsey et al., 2013). However, the authors oftwo ofthese studies (Ellis et al., 2007; Wilsey et 
al., 2012) reported that the effect of cannabis still provided superior pain relief to placebo even 
taking into consideration the effects of unblinding and the placebo effect. The data, when treated 
to compensate for the lack of blinding, did not appear to influence the results when evaluating 
cannabis efficacy. The fact that the data had to be treated however could be a source of 
significant concern with respect to reliability. The open-label trial that evaluated the interaction 
between cannabis and opioids had a small sample size but saw a 27% (95% CI 8.9 to 45 .5%) 
reduction in pain from baseline, though this study was not placebo-controlled (Abrams et al. , 
2011). In the observational studies, the cross-sectional questionnaire by Woolridge et al. (2005) 
reported that 37% (n =53) of subjects used cannabis for nerve pain with 91% (n = 48) reporting 
either "much" better or "a little" better compared to only 9% (n = 5) reporting no change (p < 
0.001). However, the degree of improvement from baseline was not numerically reported making 
it difficult to gauge the efficacy of cannabis in comparison to other medications used for NeP. 
This is also a significant limitation in terms of validity. The gold standard for research in pain 
control is the use of the visual analogue scale as a quantitative measurement and this method was 
not used in this study. The case series by Lynch et al. (2006) reported a 60% reduction in 
baseline pain in 93% (n = 28) of those who used cannabis for pain control. However,the 
percentage of these subjects with NeP was not reported. The study, unfortunately, lacked a 
control group, which constitutes a significant weakness in design. The sub-analysis of a RCT by 
Corless et al. (2007) on self-care strategies for HIV symptom management failed to show 
significant differences between the effect of cannabis versus over-the-counter medications (n = 
15, p = 0.472), prescribed analgesics (n = 15, p = 0.465), or antiepileptics (n = 13, p = 0.636) on 
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NeP. These studies are limited by their small sample size. However, participants subjectively 
rated cannabis as more effective than unspecified over-the-counter or antiepileptic medications 
(Corless et al., 2007) though self-reports of effect are a known source of bias. Long-term efficacy 
was not evaluated in the clinical trials and the two open-label studies (see Table C2). Further, 
two of the observational studies that assessed the use of marijuana for symptoms associated with 
HIV did not report the length of time the subjects had used marijuana, thus making it difficult to 
determine long term effects (Corless et al., 2009; Woolridge et al., 2005). This makes it difficult 
for the PCP to endorse a treatment when the long term efficacy and safety is not known. 
Number needed to treat. The NNT value reflects the number of people needed to be treated 
with a medication or intervention for one person to see a benefit and is the value obtained from 
the inverse of the absolute risk reduction (Rang et al., 2012). For example, a NNT value of2 
means that for one person to see a statistically significant benefit from taking a medication or 
treatment two people have to be treated. This value represents the clinical significance of a 
medication or treatment. In this review, NNT values for dried cannabis were calculated to reflect 
the number of people needed to be treated before one person would achieve a clinically 
significant 30% reduction in pain (Rang et al., 2012). Abrams et al. (2007) calculated a 3.6 NNT 
value from 52% (n= 13) of those who smoked cannabis versus 24% (n =6) who smoked placebo 
(95% CI 2% to 54%, p<0.04). Ellis et al. (2009) calculated a 3.5 (95% CI 1.9 to 20.8) NNT value 
from 46% (n=13) who smoked cannabis versus 18% (n=5) who smoked placebo (p = 0.043). 
Wilsey et al. (2013) calculated a 2.9 NNT value from 61% (n=22) who smoked a medium dose 
(3.53%) of cannabis and a 3.2 NNT value from 57% (n=37) who smoked a low dose (1.29%) of 
cannabis versus 26% (n=10) who smoked placebo (p = 0.0023 and p=0.0069, respectively). 
These same authors also used their NNT values to compare cannabis efficacy against the NNT 
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values of current medications used for treating NeP. This will be discussed in the text to follow. 
However, significant limitations in the method used to analyze the results and calculate the NNT 
value were found. Only two studies used the intention-to-treat method, which includes all 
subjects who were initially randomized in the final analysis even ifthere were subjects that 
dropped out before finishing the trial (Corey-Bloom et al. , 2012 and Ellis et al., 2009). Five 
studies used the per-protocol method where only those subjects who complete the entire trial are 
included in the analysis of effect and one used the modified intention-to-treat method where the 
authors modify who they include in the analysis (see Table C2). As will be discussed further, 
these analysis methods impact the validity of the outcomes and applicability to practice. 
Time period to effect. There was heterogeneity among the studies evaluating at what point in 
time cannabis was most effective at relieving pain. Abrams et al. (2007a) observed the greatest 
decrease in chronic pain scores occurred at 15 minutes post cannabis inhalation with a continued 
but less marked decrease in pain at the 55 and 95 minute marks. Jay et al. (2004) observed the 
greatest effect on pain to occur between 15 to 55 minutes post cannabis inhalation. Wallace et al. 
(2007) evaluated the effect of cannabis on pain induced by a capsaicin injection; no analgesic 
effect occurred at 20 minutes post exposure but did occur at 55 minutes post exposure. Wilsey et 
al. (2008) observed the greatest pain decrease between the 60 and 120 minutes post cannabis 
exposure and Wilsey et al. (2013) reported the greatest decline in pain between 120 and 180 
hours. It is difficult to directly compare these two studies (Wilsey et al. , 2008; Wilsey et al., 
2013) with the first two since Jay et al. (2004) and Abrams et al. (2007a) assessed the cannabis 
effect after only one dose while the other two assessed the cannabis effect after each subsequent 
dose increase. These differences in onset of action make it difficult for HCPs to provide an 
evidence base that will effectively inform the prescription of the appropriate dosing frequency. 
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Adverse Effects, Drug Interactions and Contraindications to Client Groups 
Identifying the safety issues is a key step in the process of prescribing (de Vries et al., 1994). 
The studies reported adverse effects, risk of toxicity, and contraindications but limited data was 
available to describe the incidence. All of the experimental studies were short in duration ranging 
from a few days to a few weeks. Lynch et al. (2006) provides some information on the potential 
long-term effects as they evaluated subjects who had been using medical marijuana for one to 
five years; however, the major limitations of this study was that it was simply observational. In 
addition, the small sample size and presence of self-selection bias was also limiting as the clients 
interviewed all had prior recreational use of cannabis experience. 
Adverse effects. The severity and frequency of adverse events increased as the cannabis dose 
increased with adverse effects reported in a concentration as low as 1% (Ellis et al., 2009). In all 
seven RCTs, adverse effects were more common in the active THC versus placebo arms (see 
Table C2). The most common adverse reactions identified by frequency in subjects are detailed 
in Table 2. 
Physical effects. Physiological effects seen that were directly attributed to smoked cannabis 
included dizziness (n=l, Lynch et al., 2006), tachycardia and an intractable cough (n=2, Ellis et 
al., 2009). Other physiological effects observed are detailed in Table 2. 
Cognitive effects. The most frequently reported adverse effects involve the CNS (Health 
Canada, 2013a). In this review, three studies calculated significant effects of smoked cannabis on 
cognitive function compared to placebo (p < 0.04) (Corey-Bloom et al., 2012; Wilsey et al., 
2008; Wilsey et al., 2013). Woolridge et al. (2005) found that subjects with pre-existing HIV-
related memory loss (26%, n=38) experienced a greater deterioration of memory (47%, n=18). 
An improvement in memory loss was reported after using cannabis in a smaller cohort (18%, n= 
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7) (p = 0.043) (Woolridge et al., 2005). Wallace et al. (2007) reported no statistically significant 
cognitive impairment (6%, n=1) and the other two studies only reported no subject withdrawals 
due to adverse cognitive effects (Ellis et al., 2009; Ware et al., 2010). 
Table 2: Frequency of Adverse Effects(% of Subjects) 
Physiological 
Dizziness 5.9% to 23%abet 
Headache 2% to 33%org 
Fatigue 5% to 30%bdtg 
Cough 3% to 14%cr 
Increased pain 10% to 14%1 
Weight gain 23%d 
Throat irritation 3% to 18%01 
Increased heart rate 13% to 46%cd 
Nausea 4% to 11 %aoerg 
Asthenia 5% to 15%1g 
Dyspnea 5% to 6%et 
Dry mouth 6%e 
Co nitive 
Sedation 54%3 
Concentration difficulties 9%1 
Sensation ofbeing "impaired", 5% to 6%01 
"stoned" or "high" 
Slowed thoughts 23%d 
Decline in learning and 47%g 
memory 
Confusion 7% to 16%3 
Psycholo2ical 
Psychosis 3%c 
Paranoia 7% to 13%ad 
Anxiety 4% to 25%adg 
a b, c Note. Abrams et al. 2007a. Corey-Bloom et al. , 2012. Elhs et al. , 2009. 
dLynch et al. , 2006.cWallace et al. , 2007.rWare et al. , 2010 .gWoolridge et al. , 2005. 
The degree of neurocognitive impairment was related to the dose of cannabis; higher doses 
showed greater impairment (Wallace et al., 2007; Ware et al., 2010; Wilsey et al., 2008; Wilsey 
et al., 2013). For instance, in one study, cognitive decline worsened as the concentration ofTHC 
increased from 0% (placebo) to 1.29% to 3.53% (Wilsey et al., 2013). 
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It is interesting to note that in the Corless et al. (2009) study those subjects who reported 
using marijuana for symptoms associated with HIV had significantly lower rates of adherence to 
their HIV medications when compared to subjects who did not use marijuana. The authors 
reported that this finding might not be related to the cognitive effects of marijuana or higher 
symptom intensity scores. Instead, they suggest that it may be due to the length of time the 
subjects had HIV since this issue with adherence was seen in those who had lived with HIV 
longer (Corless et al. , 2007). It is worth noting this issue since adherence problems with the use 
of medical marijuana may also be a factor in clients who have had other chronic conditions, 
including neuropathic pain. Indeed poor adherence to any prescribed drug remains a prevalent 
issue in Canada (British Columbia Pharmacy Association, 2013). 
Psychological effects. Twelve studies that evaluated changes in mood associated with 
cannabis use reported a general improvement. Three studies showed no statistically significant 
changes in mood (Wallace et al. , 2007; Wilsey et al. , 2008; Wilsey et al. , 2013) while six of the 
studies showed an improvement in both anxiety and depression (see Table C2). Ellis et al. (2009) 
reported a subject withdraw due to psychosis. Three studies reported anxiety as an adverse effect 
of cannabis use with one withdrawal due to this effect (Wallace et al. , 2007). It is interesting to 
note that the relief from anxiety and depression was cited as a major reason for cannabis use in 
three of the observational studies (Corless et al. , 2007; Lynch et al. , 2006; Woolridge et al. , 
2005). 
Toxicity. Evidence of toxicity in the studies was low overall but there was a clinically 
significant event with one subject withdrawal due to psychosis (n = 1, N=34) (Ellis et al., 2009); 
however, it is acknowledged that the dose used ( 4% THC by weight) was below the expected 
dose range (5 grams per day) when toxicity usually occurs. 
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Cannabis effects on nai"ve users. Of the 10 clinical studies that evaluated cannabis use on 
NeP seven excluded cannabis naive subjects. Further, only 4% and 20% in the other two studies 
had prior cannabis experience (Ellis et al., 2009 and Corey-Bloom et al., 2012, respectively). 
This raises the concern that the studies have not fully investigated the effects on naive users, 
which could potentially result in different clinical outcomes and adverse events. One study 
attempted to address this issue through the inclusion of non-experienced users of cannabis in the 
study; their findings did not show any increased adverse effects on non-experienced users versus 
experienced users (Ware et al., 2010). 
Drug interactions. Cannabis is metabolized by the same hepatic xenobiotic cytochrome 
P450 enzymes (CYP2C9 and CYP3A4) (Watanabe et al., 2007) that are involved with the 
metabolism of many other medications. Hence, there is a potential for drug interactions. All of 
the studies except one (Wallace et al., 2007) reported their subjects were taking other 
medications while using dried cannabis but there was a lack of objective analysis on potential 
drug interactions of cannabis with concomitant medications except in only one study (Abrams et 
al., 2011 ). Ellis et al. (2009) did not report any synergistic drug interactions between opioids and 
cannabis. Abrams et al. (20 11) evaluated the interaction between vaporized cannabis and opioids 
and found that cannabis augmented the analgesic effect of opioids without significantly altering 
the opioid plasma levels. No adverse effects were observed in this study. Morphine absorption 
was slowed when cannabis was ingested and there was no effect on oxycodone absorption 
(Abrams et al., 2011). This may have implications for the safety profile in persons using 
morphine as once the cannabis is discontinued, a higher serum value may be reached to which 
the individual is not tolerant. The authors interestingly, concluded that this study presents some 
evidence that cannabis used in conjunction with a lower dose of opioid results in fewer side 
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effects than the use of a higher dose of opioid without cannabis. This conclusion is supported by 
the findings in Lynch et al. (2006) where the majority of subjects (n = 15, 70%) reported the use 
of marijuana allowed them to decrease the use of other medications that were causing side 
effects including NSAIDs, opioids and antidepressants. However, this study is limited by self-
selection bias and the small sample size. Marijuana users reported improved efficacy of their non 
cannabinoid medications when compared to non-marijuana users in the study by Corless et al. 
(2007). However, this finding was not significant using an independent t test calculation (-0.039, 
p =0.969). 
Contraindications. The risks associated cannabis use provides some guidance in 
determining which patient populations are inappropriate for medical marijuana. All of the 
experimental studies excluded subjects with active substance abuse. Five of the RCTs and one 
open-label study excluded subjects with a history of (a) mental illness including major 
depressive disorder, schizophrenia, bipolar, and psychosis, and (b) pulmonary disease including 
tuberculosis, asthma, emphysema and bronchitis (Abrams et al., 2011; Corey-Bloom et al., 2012; 
Ware et al., 2010; Wallace et al., 2007; Wilsey et al., 2008; Wilsey et al., 2013). In the three 
observational studies, the underlying medical or psychiatric conditions of the clients were not 
addressed (Corless et al., 2007; Lynch et al., 2006; Woolridge et al., 2005). Additional exclusion 
criteria that varied in the studies included those with uncontrolled hypertension, cardiovascular 
disease, pregnancy or breastfeeding, history of cannabis dependence, abnormal kidney and liver 
function, any serious medical condition not specified, epilepsy, head trauma, or tobacco 
dependence. The observational studies presumably included subjects with a variety of underlying 
medical conditions in addition to chronic pain but these were not addressed in the evaluation. 
The exclusion criteria in the experimental studies were extensive which makes it difficult to 
apply the findings of the studies to the general population seen in practice. 
Cannabis Dosing and Method of Delivery 
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Another concern with the use of dried cannabis is the lack of data surrounding appropriate 
dosing and method of delivery to minimize adverse effects while achieving the desired 
therapeutic outcome. The studies provided useful but only provided limited information on how 
to address this issue. 
Cannabis dosing. In the studies that evaluated smoked cannabis a range of 1% to 9.4% was 
used (see Table C2). Four studies reported no difference in pain reduction when a lower dose of 
THC (range of 1.29% to 3.5%) was directly compared to a higher dose (range of3.5% to 9.4%). 
One study found that a higher dose ofTHC (7%) had a greater effect on superficial pain than a 
lower dose (3.5%) (see Table C2). 
In the observational studies, Lynch et al. (2006) evaluated information from clients who used 
a range of 1g to 5g of cannabis per day with the average dose of the oral form being less than 1g 
per dose (Lynch et al., 2006). In this study, the number of doses per day ingested was not 
differentiated to include the methods used. Two of the studies in this review evaluated a self-
titrating dosing schedule (Ellis et al., 2009; Wilsey et al., 2013) that allowed the subjects to 
balance the analgesia against adverse effects. 
In the studies that reported time between inhalations there were similarities with three 
studies waiting 40 seconds (Wallace et al., 2009, Wilsey et al., 2008, Wilsey et al., 2013) and 
two studies waiting 45 seconds (Abrams et al., 2011; Corey-Bloom et al., 2009). The other four 
trials did not report time between inhalations. Only two studies reported the time between doses 
at 60 minutes (Wilsey et al., 2008; Wilsey et al., 2013). Corey-Bloom et al. (2009) and Wilsey et 
41 
al. (2008) reported that doses of smoked cannabis in their trials ranged from two to four puffs. 
This variation in frequency of dosing makes it difficult to apply these findings for practice 
recommendations. The following discussion on the method of delivery also provides conflicting 
information for use in practice. 
Method of delivery. The majority of study subjects utilized the smoking method. There were 
no experimental clinical trials that evaluated the oral form of cannabis on NeP and one study did 
not clarify what method their subjects used (Corless et al. , 2007). Lynch et al. (2006) found that 
all of their subjects (N= 30) used the smoking route with only 37% (n = 11) using the oral route 
only or in combination with smoking. Likewise, the majority of subjects (n = 101, 71%) who 
completed the questionnaire by Woolridge et al. (2005) used the smoking route only; only 2% (n 
= 3) reported using the oral route only. Vaporization was utilized in two studies with efficacy 
outcomes similar to the studies that utilized smoked cannabis (Abrams et al., 2011 ; Wilsey et al., 
2013). 
In summary, this literature review identified 12 studies relevant to the objective and was 
critically evaluated. The data identified provides some decision making guidance for PCPs in the 
authorization of a medical marijuana license. The following section will discuss the findings with 
an analysis for making recommendations for practice and future research. 
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CHAPTER4 
Discussion 
This integrative literature review was undertaken to determine if dried cannabis can be 
authorized safely by PCPs to treat NeP in adults. Step three of the WHO guidelines formed the 
basis for evaluating the literature. Some data was unavailable or incomplete limiting the validity 
of the results . The nine clinical trials and three observational studies utilized in this review do not 
provide enough data to support the safe use of medical marijuana for NeP in adults. Medication 
prescribing, however, is always a balance of risks versus benefits and when standard treatment 
fails, some health care providers may consider alternate therapies. Some PCPs are providing or 
are considering providing their patients authorization for dried cannabis, this may be due to 
many factors including federal legislation granting access, patient requests, and anecdotal 
evidence of its efficacy. In future , when provincial regulations are in place, NPs, as primary care 
providers, may also be considering the authorization of dried cannabis in certain patients. A 
synthesis of the evidence will provide the necessary foundation to support the recommendations 
and conditions for those PCPs who are considering authorizing its use. 
Efficacy of Cannabis on Neuropathic Pain Compared to Current Treatments 
An important step in selecting a treatment is to determine the efficacy of the medication for 
the desired therapeutic objective. In this case, the review centered on the efficacy of medical 
marijuana as compared to current medications used for the treatment ofNeP. All of the studies 
used in this review demonstrated a potentially modest analgesic effect for NeP but were limited 
to a large degree by flaws in design. One particular area of bias is common to many clinical 
efficacy studies where only those study subjects who completed the entire trial were included in 
the final analysis. Thus, a study is inherently biased because those who dropped out from 
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intolerance or ineffectiveness are not included in the analysis. This may give the mistaken 
impression that a drug is potentially more effective than it actually is. Therapeutic failures were 
excluded in the literature examined and thus, the studies do not represent the most accurate 
description of efficacy. 
Three studies calculated the NNT values with a range of2.9 to 3.6 for a THC concentration 
range of 1 to 9.4% (see Table C2). Cannabis has NNT values that are higher than the first line 
medications for NeP and these values were calculated from a 30% reduction in pain whereas the 
NNT values for the guideline recommendations were calculated from a 50% reduction in pain 
from baseline. Further, only one study calculated the NNT value based from a sufficient sample 
size and the intention-to-treat method (Ellis et al. , 2009). The other two studies (Abrams et al. , 
2007 and Wilsey et al., 2013) used biased outcomes to calculate the NNT so these values cannot 
be considered reliable. Tricyclic antidepressants (TCA) and antiepileptics are first line 
medications, the serotonin-norepinephrine-reuptake inhibitor (SNRI), venlafaxine, is second line, 
the opioid tramadol is third line, and cannabinoids are fourth (Moulin et al. , 2007). NNT values 
for these medications are presented in Table 3. A NNT value for nabilone on neuropathic pain 
was not found in the literature search. The cannabis trials' authors used their NNT values to 
compare cannabis efficacy against the NNT values of current medications used for treating 
neuropathic pain but it is important to acknowledge the differences between the degree of pain 
reduction from baseline used to calculate the NNT values in the cannabis studies used in this 
review. The NNT for the first, second and third line medications used the more stringent 
requirement of a 50% change from the baseline while the cannabis trials only required a 30% 
reduction. Hence, a real comparison cannot be made with the data provided between these 
medications. The WHO prescribing guidelines advise clinicians to choose medications with the 
largest data concerning the efficacy, safety, suitability and cost (de Vries et al. , 1994 ). It is best 
practice to start with medications that demonstrate the safest profile with the highest level of 
efficacy first. 
Table 3: NNT Values for Medications Used to Treat Neuropathic Pain 
Medication NNT using 30% NNT using 50% 
Amitriptyline (uf 
to 125mg/dayfb 
change from baseline change from baseline 
1.2 (95% CI 1.2- 1.5) 
2. 7 (95% CI 2.0- 4.0) 
4.6(95% CI 3.6 - 6.6)* 
Author 
Saarto & Wiffen, 2007 
Saarto & Wiffen, 2007 
Moore et al., 2012 
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V enlafaxine (ER 
150-225mg/day) 
4.5 Rowbotham, Goli, Kunz, 
& Lei , 2004. 
Pregabalin 
600mg/daya 
Pregabalin 
600mg/dal 
Gabapentin ( 600 -
3600mg/daya 
Tramadol 
4.0 (95% CI 3.1- 5.5) Wiffen et al., 2013 
6.3 (95% CI 4.6- 1 0) Wiffen et al., 2013 
5.8 (95% CI 4.3- 9) Wiffen et al. , 2013 
3.8 (95% CI 2.8 - 6.3) Duehmke, Hollingshead, 
& Comblath, 2009 
Sativexe 8.6 8.5 Nurmikko et al., 2007 
SC 3.56% THCC 3.6 Abrams et al., 2007 
SC 1-8% THCc 3.5 Ellis et al., 2009 
SC 1.29% 3.2 Wilsey et al., 2013 
SC 3.53% 2.9 Wilsey et al., 2013 
Note: CI = confidence interval. SC =smoked cannabis. a diabetic neuropathy. bpostherpetic neuralgia. cHIV-
associated sensory neuropathy. dpost-stroke pain ."unilateral peripheral NeP. *NNT calculated with data from NeP 
and fibromyalgia. 
Adverse Effects, Drug Interactions and Contraindications to Client Groups 
Adverse effects. It is important to minimize adverse drug reactions and to avoid harmful 
drug interactions. The studies revealed dose related adverse effects from dried cannabis. The 
main ingredient of medical marijuana, THC, exerts its greatest effects on the CNS through its 
action as a partial agonist on the CB 1 and CB2 receptors of the endocannabinoid system (Rang et 
al. , 2012). It is therefore not surprising that neurocognitive and psychological effects are reported 
with the highest frequency. Anxiety, dizziness, euphoria, impaired cognition, fatigue, confusion, 
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and paranoia were reported in the studies with varying frequency and severity. Four of the 
studies reported subject withdrawals due to adverse effects (see Table C2). Two of these studies 
did not include subjects who withdrew from adverse effects in the final analysis (Ware et al., 
2010; Wallace et al. , 2010). This places bias on the outcomes making it seem more efficacious 
on the intended population than it actually is. However, it is also valid to consider that the 
outcomes of these two trials are applicable to clients who will tolerate dried cannabis in practice. 
The acute cognitive effects on learning and memory seen with cannabis use is concerning. 
Wilsey et al. (2013) states the effect observed in their study was minimal and not likely to have a 
major impact on daily functioning. However, Wilsey et al. (2008) observed the same effect but 
cautioned the prescribing of cannabis to those who require intact cognitive processing for their 
work. Indeed, the risk of and incidence of impaired driving and motor vehicle accidents is 
correlated to impairment from cannabis use (Volkow et al. , 2014). The Office ofthe 
Superintendent of Motor Vehicles (OSMV) in BC requires the disclosure of psychotropic 
medication use on the driver fitness form (BC Ministry of Justice, 2014). Cannabis is not 
specifically identified in the guidelines but it is important to acknowledge the evidence that 
indicates cannabis effects driving ability. PCPs have the responsibility to inform the OSMV if a 
client is using cannabis to ensure public safety. 
How cannabis use affects the user cognitively over the long term is one of the major 
concerns for PCPs also (Corey-Bloom et al. , 2012) but was not assessed in this review because 
the studies were conducted over short periods of time. Evidence from other studies has shown 
impairment in neurocognitive development in fetuses exposed in utero, altered brain 
development, and lowered IQ in frequent users during adolescence with evidence of impairment 
even after one year of abstinence (Huestis, 2007; Volkow, 2014 ). Indeed, one study recorded a 
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six-point reduction in IQ in adult subjects who initiated cannabis use in adolescence, which may 
be more detrimental to the overall cognitive function in an individual who already has lower 
baseline intelligence (Meier et al., 2012). 
The effects on subjects mental health was conflicting in this review since cannabis induced 
anxiety and depression in some subjects (see Table 2) and relieved it in others (see Table C2) 
though the studies that evaluated these symptoms were short term. Chronic NeP itself is 
associated with higher rates of depression and anxiety (Choiniere et al. , 201 0). Long-term effects 
from other studies have shown evidence of diminished life satisfaction and achievement, chronic 
psychosis, depression and addiction (Volkow et al., 2014). The long-term effects oftolerance or 
addiction to cannabis were not evaluated in these studies but are important to consider because it 
is likely in practice that cannabis will be prescribed for long-term chronic pain management. Up 
to 25% to 50% of those who smoke it daily will become addicted (Hall & Degenhardt, 2009). 
Screening clients for addiction and avoiding use in those with a history of addiction prior to 
prescribing cannabis is one method to address this concern. The study by Lynch et al. (2006) 
evaluated 30 people who have been using cannabis for one to five years for refractory pain. All 
of the subjects reported the benefits of dried cannabis outweighed any negative effects 
experienced even though 76% of subjects reported cognitive side effects including confusion, 
anxiety and paranoia. This is an interesting finding and one to consider in a client who has 
refractory pain and impaired quality of life or functioning in addition to depression or anxiety. 
Toxicity from cannabis use is not common and sometimes difficult to differentiate it from an 
adverse effect because of the lack of measured plasma cannabis levels; however, ingestion of 
greater than 5 grams per day increases the risk for toxicity (Health Canada, 2013a).Psychosis is 
considered a toxic effect and was experienced by one subject (Ellis et al., 2009). A positive 
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aspect of cannabis is that it shares some similarities with opioids but it lacks the ability to 
suppress the respiratory system (Carteret al, 2004). However, as the background literature 
reveals, there have been reports of death attributable to the toxic effects of cannabis (Hartung et 
al. , 2014). A key part of the discussion with the client includes disclosure of these toxic and 
adverse effects that may outweigh any benefits derived from cannabis use. 
Cannabis-drug interactions. The potential for cannabis to interact with other medications 
and cause adverse effects is high because THC and cannabidiol are metabolized in the liver by 
the cytochrome P 450 enzymes CYP2C9 and CYP3A4 (Watanabe et al. , 2007) that metabolize 
many other common drugs. 
Abrams et al. (2011) provided objective data on the effect that cannabis had on plasma 
opioid levels with encouraging results. The two observational studies by Corless et al. (2007) and 
Lynch et al. (2006) provide evidence that cannabis (1) augments the efficacy of other 
medications without increased side effects and (2) leads to the decrease in use of these other 
medications, as reported by the subjects. However, self-reports of effects are subject to bias 
when interpreting the results for use in practice. The objective data collected from Abrams et al. 
(2011) and subjective from Corless et al. (2007) and Lynch et al. (2006) provide support for the 
use of cannabis on clients who are using other medications. In addition, it provides reassurance 
that in the other clinical trials most of the clients were on concurrent medications throughout the 
study without apparent increase in adverse effects other than that already associated with 
cannabis; however, any possible interactions between cannabis and other medications were not 
objectively measured in these studies. One potential problem is that of concurrent use of street 
drugs, most notably opiates. Since the studies exclusion criteria included those with addiction 
histories, it is not known how this population is affected. However, it remains important to 
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monitor clients on concurrent medications for any change in therapeutic effects. Cannabis acts on 
the CNS and the use of alcohol or benzodiazepine could increase sedation (Canadian 
Pharmacists Association, 20 14a ). The studies in this review did not evaluate cannabis and these 
other medications but the background literature provides evidence to make the recommendation 
that cannabis should not be licensed to those who are taking concurrent benzodiazepines, alcohol 
or other sedatives. The identified adverse effects from this review and known drug interactions 
provide some guidance on who should not be prescribed medical marijuana. 
Contraindications. The client demographic is an important consideration when choosing a 
therapy. A major limitation ofthe clinical trials was the exclusion criteria since all of the studies 
excluded individuals who had mental illness including depression, bipolar, schizophrenia, and 
anxiety; therefore, there is no clinical data observing the effect of cannabis on these groups. The 
observational studies by Corless et al. (2007), Lynch et al. (2006), and Woolridge et al. (2005) 
evaluated subjects who used cannabis to relieve a variety of symptoms including anxiety and 
depression; however, the underlying baseline mental status of these clients were not evaluated 
and so one cannot draw conclusions about the safety of cannabis for use with those who have 
mental health conditions from these studies either. In addition, none of the studies looked at the 
impact on long-term mental health as they were all short term studies. It has been shown that the 
adverse psychoactive effects of cannabis may aggravate underlying mental health symptoms as 
evidence points to cannabis use may be a trigger for the earlier age of onset of bipolar and 
schizophrenia in genetically susceptible individuals (de Hert et al. , 2011). Groups known to be at 
higher risk for experiencing adverse effects of medications include children, the elderly, those 
who are pregnant or breastfeeding, those who have liver or renal failure, or individuals with 
multiple comorbidities (de Vries et al., 1994). Cannabis should not be used in those under the 
age of 25, with active or remote substance use, schizophrenia, history of psychosis, or bipolar 
disorder (Health Canada, 2013a). Further, the smoked form should not be used in those with 
cardiovascular or respiratory disease. 
Cannabis Dosing and Method of Delivery 
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Cannabis dosing. The aim of medication dosing is to maintain the plasma level of the drug 
within the therapeutic window (de Vries et al. , 1994). The dosing of cannabis in practice remains 
a concern for PCPs because there has been no standardized formula. Many variables affect THC 
and cannabinoid absorption (Carteret al. , 2004). Health Canada acknowledges that quantifying 
the amount ofTHC absorbed in a single puff through smoking is difficult due to factors such as 
prior experience and smoking technique. And, further, the concentration of cannabinoids in each 
supply of dried cannabis varies with growing conditions (Health Canada, 2007). However, based 
on data from the WHO (1997) and peer reviewed literature, Health Canada (2007) recommends 
that the daily dose of dried cannabis ingested in any form be kept between 1 and 3 grams, or 
three to six joints per day with a concentration of 12.5±1.5%. In this review, Lynch et al. (2006) 
showed the average dose used by their subjects was less than 1 gram, which is consistent with 
the Health Canada and CFPC recommendations. 
The clinical studies that evaluated different doses on analgesic efficacy provides little 
guidance for the PCP except to advise that clients will likely derive benefit with a low dose and 
should be advised to start with the lowest dose possible which is in keeping with the principles of 
good prescribing for any drug. 
In terms of frequency of dosing there was heterogeneity among the studies evaluating at 
what point in time cannabis was most effective at relieving pain. Therefore, clients should be 
instructed to titrate very slowly. Health Canada (2007) advises clients to wait a few minutes 
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between each puff of smoked or vaporized cannabis; the studies in this review had clients wait 
40 or 45 seconds between inhalations providing limited but helpful information for use in 
practice. The CFPC (2014) advises those new to cannabis or those trying a new strain to inhale 
one puff and wait four hours before the next one to determine strength of effect since the 
observed duration of action of each dose is two to four hours (Health Canada, 20 13a). There was 
no data on the frequency of oral dosing utilized by subjects in the trials and it is acknowledged 
that the main recommendations for frequency between doses is based on anecdotal reports and 
limited information regarding the rates of absorption (Health Canada, 2013a) . The oral method is 
preferred over the inhalation route so the recommendations made are based on the background 
literature. Since peak plasma levels are reached between one and six hours it is advisable for 
clients to wait at least 60 minutes between doses to gauge the strength of effect (Carter et al., 
2004). In summary, this review confirms the ongoing issue with dosing and does not provide 
clear guidance to the PCP on how to calculate accurate dosing or provide information on the 
actual amount of cannabis the client is actually absorbing. 
Method of delivery. The most common method of cannabis delivery is smoking (Tashkin, 
2013); a finding also confirmed by the subjects from the observational studies in this review. 
Smoked cannabis is acknowledged to be an efficient method for self-titration in order to achieve 
a balance between analgesia and side effects (Wilsey et al. , 2008). However, the known adverse 
effects seen with smoking including chronic bronchitis (Volkow et al., 2014) and association 
with lung cancer (Callaghan eta. , 2013) make it particularly difficult for the PCP to promote this 
method. 
The vaporized form of ingestion is thought to be safer than smoking but there is not enough 
clinical data to determine if this is true. Some of the data suggest that this method may be more 
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efficacious for neuropathic pain. The inhaled method though cannot be endorsed as a safe route 
by PCPs when authorizing dried cannabis use. 
Studies on the characteristics of the oral form of cannabis are lacking with no high quality 
clinical studies found in the literature search. It is acknowledged that the oral form of cannabis is 
complicated by a long five to eight hour half-life and lower bioavailability (Health Canada, 
2013a). Thus, it remains harder to self-titrate and has a slower onset of action compared to 
smoking. The oral route does not have the same adverse effects on the respiratory and 
cardiovascular system compared to the smoking and vaporized form making it theoretically more 
appropriate for clients with respiratory and cardiac disease. However, due to the greater amount 
of metabolization to active metabolites, this route has a greater sedative effect compared to the 
smoking route. It is advisable for the clinician to limit or avoid its use in those who need to be 
mentally alert for work or other activities including driving or operating heavy machinery. 
Cost. Cost is an important consideration surrounding the suitability of a medication for a 
client (de Vries et al., 1994) but was not addressed in the literature review either in the clinical 
trials or observational studies. The new MMPR acknowledges that the increase in regulation of 
medical marijuana is also likely to result in an increase in the cost to consumers. This will 
represent a hardship for some clients, eliminating it as a therapeutic option. 
Review Limitations 
There are limitations present in this literature review. The evaluation of the data was 
completed by only one person potentially leading to errors in data analysis. PCP concerns 
surrounding the issue of diversion of dried cannabis impacts the willingness to utilize it in 
practice but it was beyond the scope of this review to explore this issue; it is acknowledged by 
the author to be an important part of safety in prescribing. 
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It is acknowledged that not all aspects of rational prescribing, as described in the six steps of 
the WHO guidelines were explored in depth in this review. Monitoring the response to therapy is 
an important step in the process of rational prescribing as it enables the clinician to determine if 
the medication has been successful or whether further action is needed (de Vries et al., 1994). It 
is also important to incorporate information about the drug, instructions for administration and 
warnings, which will help to enhance patient adherence and give them the best possible outcome. 
The next section will discuss conclusions derived from the literature with recommendations 
for practice based on the synthesis and analysis of the findings . Recommendations for future 
research will also be included. 
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CHAPTERS 
Recommendations and Conclusion 
Dried cannabis is not regulated by Health Canada the same way that prescription 
medications are. However, PCPs are expected to use the same standards when assessing the 
suitability and safety of a prescription medication when authorizing medical marijuana (CPSBC, 
2014). Thus, it was the intention of this review to analyze and synthesize the literature to 
determine if dried cannabis can be authorized safely by PCPs to treat NeP in adults using the 
principles of safe prescribing by the World Health Organization. The following discussion is a 
summary of the findings to answer the objective, make recommendations to inform practice, and 
make suggestions for future research. 
Recommendations for Practice 
Over one million Canadians suffer from NeP (Moulin et al., 2007) and in many cases the 
current treatments show limited effectiveness (Abrams et al., 2007a; Wilsey et al., 2013). NPs 
who address NeP in practice have a responsibility to be educated in the available therapeutic 
options and are accountable for the treatments they utilize in practice. A survey done by the 
CRNBC (20 13) showed that 31% of NPs would incorporate dried medical marijuana in their 
practice with 40% feeling unsure. This survey speaks to the significant need for NP education as 
evidence based guidance should inform all prescribing. Evidence based guidelines were not in 
place at the time of this survey. 
It is the finding of this integrative review that dried cannabis cannot not be authorized safely 
by PCPs to treat NeP in adults based on the WHO safe prescribing guidelines. Further, the 
efficacy of dried cannabis has not been established to warrant its use as a treatment for 
neuropathic pain. However, as NP authority to authorize dried cannabis has been included in 
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federal legislation and is currently being considered at the provincial level by the CRNBC, it is 
important that NPs be well informed of the evidence surrounding this substance. In future, NPs 
as primary care providers, considering authorizing dried cannabis under the MMPR should do so 
with a full understanding of the evidence, associated risks, and a clear awareness that the short 
and long term medico-legal implications for those who authorize dried cannabis is currently 
unknown. It is recommended that dried cannabis not be prescribed in general. As PCPs are 
currently authorizing dried cannabis, and some NPs surveyed in BC have reported planning to 
authorize dried cannabis into their practices, the findings of this integrative review will provide 
recommendations for safer prescribing. For those providers that are considering its use in a small 
minority of clients who have severe NeP refractory to all other non-pharmacological treatments 
and more effective medications, a decreased quality of life, have no contraindications, and who 
understand and accept the associated risks, a systematic and thoughtful approach to authorization 
should be adopted. A thorough review of the risks and benefits of dried cannabis must be carried 
out with each patient. Further, a thorough history, health and pain assessments, and utilization of 
evidence-based care for those with NeP is required. The following recommendations, taken from 
the current evidence, provide some guidance to PCPs, including NPs, for safer authorization (see 
Table 4). 
Table 4: Recommendationsfor Safer Authorization of Medical Cannabis 
Efficacy 
Dried cannabis has not been proven more effective for NeP than prescription medications. If 
planning on authorizing its use, only consider its use in clients with proven severe, refractory 
NeP. Document that all guideline recommended medications and treatments have failed. Clients 
should be fully informed regarding the lack of efficacy of dried cannabis. 
Synthetic cannabinoids should be tried before dried cannabis as they are regulated and approved 
for use by Health Canada with established dosing and safety profiles 
Evaluating Safety and Communicating Risk 
Clients should be fully informed regarding what is known and not known about short and long 
term adverse effects and risks 
Clients should be aware of the high rates of addiction in those who use cannabis daily 
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Complete careful assessments of all clients being considered for authorization of dried cannabis 
to identify those patients with contraindications, such as anyone who: 
• is younger than 25 
• needs intact cognitive processing or operates or drives complex machinery for work 
• has past or active substance use disorder including alcohol, cannabis, or other illicit drug 
• has a history of schizophrenia, bipolar, or psychosis 
• is pregnant or breastfeeding 
• has severe liver, kidney, cardiovascular, or respiratory disease 
• are currently taking other sedative-type medications including benzodiazepines 
Perform careful additional screening and assessment of clients with mental health conditions 
including anxiety and depression 
Advise clients that cannabis impairs driving ability and to refrain from driving when using or 
wait for several hours before driving. Disclose cannabis use when completing a driver fitness 
form 
Identify possible cannabis-drug interactions with concurrent medications 
Dosing 
Accurate dosing remains unclear in the literature; however, it is clear the lowest possible dose 
should be used. Clients should be authorized to use 1 gram or less per day and wait at least one 
hour between doses of orally prepared dried cannabis to gauge effects 
Method of Delivery 
Educate clients that the inhalation method is associated with long term negative changes in the 
lungs including COPD and lung cancer and should not be utilized 
Advise clients to use the oral route and advise that it may result in increased sedation compared 
to the inhaled route 
Cost 
Clients should be aware of the potential long term costs associated with cannabis use and that it 
is not covered by any medical plan 
Recommendations for Future Research 
The review of the literature identified that dried cannabis cannot be safely authorized for 
clients with NeP in primary care as identified by the WHO rational prescribing guidelines. 
Future studies should ideally consider the long-term effects, as there is a paucity of data in this 
regard. Issues with regards to dose and frequency are also a concern. The study that revealed 
decreased adherence to HIV medications on those clients using cannabis warrants further 
exploration. The NNT data is clinically helpful but the data for the number needed to harm 
(NNH) was lacking which is also important when evaluating for prescriptive safety. The new 
regulations are intended to treat marijuana like other controlled substances. However, the 
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document for medical marijuana authorization is not written on a duplicate form or numbered. It 
also has a one year expiration date (CPSBC, 2014); a length of time not standard with traditional 
prescribing. Research is needed to determine if this difference from a CDS prescription will 
contribute to issues of reduced safety and security for the individual and the population at large. 
Related to this is the need for future research on the medico-legal implications for PCPs who 
authorize its use despite the paucity of evidence relating to its safety, as defined by the WHO 
prescribing guidelines. The results of the studies also are difficult to apply to the general 
population because of the exclusion criteria. 
However, those subjects excluded were in client groups that are already acknowledged to be 
at higher risk for experiencing adverse effects from cannabis. The results of the observational 
studies did not exclude clients with underlying mental health or physical conditions but the 
degree to which cannabis positively or negatively affected these conditions were not analyzed 
and could arguably be quite significant. Future studies that include clients with mental health 
conditions are preferred as there are high prevalence rates in the general population. 
Smoking cannabis remains the most popular method of cannabis delivery and was the most 
studied method in the studies despite the concerns over long-term effects on the lungs. Therefore, 
other methods of delivery including oral ingestion, mucosal and topical forms should be 
evaluated. 
Addiction to cannabis is a prevalent consequence for many people who use cannabis 
recreationally and future studies should evaluate the risk of addiction in those who use it 
therapeutically since it is likely that they will be using it daily and over the long term. Addiction 
to any substance tends to result in less optimal outcomes. There was a lack of data concerning 
whether cannabis-nai"ve subjects experience increased rates of adverse effects; thus, this is 
important information for the NP who may be considering using this as a treatment for clients 
who have refractory NeP but have not used cannabis before. 
There was a lack of research data on other manifestations ofNeP including allodynia and 
hyperalgesia. Future studies on the impact of cannabis on these other characteristics ofNeP 
should be explored. 
Conclusion 
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Under treatment of chronic pain can have serious economic, societal and health impacts 
including the inability to work and decreased quality of life. As researchers and clinicians our 
concern is with providing our patients with the most efficacious therapies to promote and 
maintain best health outcomes. Chronic NeP is a complex condition common in primary care 
that is often refractory to currently recommended treatments. Novel approaches to pain 
management are increasingly being studied to address this issue including the use of cannabis. 
Government legislation, public and patient pressure, anecdotal evidence of efficacy and 
refractory pain has made medical marijuana an alternative treatment that requires consideration 
and evaluation of the evidence. Thus, it was the intention of this review to determine if dried 
cannabis could be safely authorized by PCPs, including NPs, for the treatment ofNeP in adults 
using step three of the WHO prescribing guidelines. It was determined that at this time, dried 
cannabis cannot be prescribed safely based on the current evidence. However, for those PCPs 
who still may consider using it in clients with severe refractory NeP the evidence provides some 
guidance on what should be considered to at least be safer when authorizing its use. This review 
made it clear that further research is needed to establish consistent and valid information 
surrounding the efficacy, dosing, method of delivery, and long-term adverse effects. Further, the 
PCP has to consider the medico-legal implications of using a medication with limited reliable 
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evidence to support its use based on rational prescribing guidelines. It is the responsibility of the 
clinician to work within evidence-based guidelines in order to ensure the safety of their clients 
and the public. 
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Glossary 
All citations from Medical Dictionary (Merriam-Webster, 2014) unless otherwise indicated. 
2-arachidonoyl glycerol (2-AG): an endogenous agonist endocannabinoid present in high levels 
in the CNS with action at the CB 1 receptors 
5-lipoxygenase enzyme: inflammatory mediator derived from phospholipid (Rang et al., 2012) 
11-hydroxy-THC: an active metabolite ofTHC (Aggarwal, 2013) 
absolute risk reduction: the absolute arithmetic difference in rates of bad outcomes between 
experimental and control participants in a trial, calculated as the experimental event rate (EER) 
and the control event rate (CER), and accompanied by a 95% CI. Depending on circumstances it 
can be reduction in risk (death or cardiovascular outcomes, for instance, in trials of statins ), or an 
increase (pain relied, for instance, in trials of analgesics) (Bandolier, 2007) 
adenosine triphosphate (ATP): an ester of adenosine and triphosphoric acid, formed 
aerobically by a chemical reaction during oxidation. It serves as a source of energy for 
physiological reactions, especially muscle contraction 
adipocyte: fat cell 
adrenergic receptors: any of a group of receptors that are present on cell surfaces of some 
effector organs and tissues innervated by the sympathetic nervous system and that mediate 
certain physiological responses (as vasoconstriction, relaxation of intestinal muscle, contraction 
of smooth muscle) when bound by specific adrenergic agents 
afferent nerve fibers: nerve cells that convey impulses toward the central nervous system 
C fibers: unmyelinated (C) fibers are associated with the dull, diffuse, and burning type pain 
A fibers: myelinated (Afibers convey a sharp and well-localized pain (Rang et al., 2012) 
agonist: a chemical substance (as a drug) capable of combining with a receptor on a cell and 
initiating the same reaction or activity typically produced by the binding of an endogenous 
substance 
allodynia: pain resulting from a stimulus (as a light touch of the skin), which would not 
normally provoke pain 
anandamide: a derivative of arachidonic acid that occurs naturally in the brain and in some 
foods (as chocolate) and that binds to the same brain receptors as the cannabinoids (as THC) 
antagonist: a chemical that acts within the body to reduce the physiological activity of another 
chemical substance (as an opiate); especially: one that opposes the action on the nervous system 
of a drug or a substance occurring naturally in the body by combining with and blocking its 
nervous receptor 
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antiretroviral medications: drugs used to treat retroviruses, namely HIV 
asthenia: lack or loss of strength 
atherosclerosis: atheromatous deposits in and fibrosis of the inner layer of the arteries 
bias: bias is an asystematic error or deviation in results or inferences. In studies of the effects of 
healthcare bias can arise from systematic differences in the groups that are compared (selection 
bias), the care that is provided, or exposure to other factors apart from the intervention of interest 
(performance bias), withdrawals or exclusions of people entered into the study (attrition bias) or 
how outcomes are assessed (detection bias) (Bandolier, 2007) 
bioavailability: the degree and rate at which a substance (as a drug) is absorbed into a living 
system or is made available at the site of physiological activity 
bipolar disorder: any of several mood disorders characterized usually by alternating episodes of 
depression and mania or by episodes of depression alternating with mild nonpsychotic 
excitement 
blinding: that act of having no knowledge of information that may cause bias during the course 
of an experiment or test <researchers blind to whether the investigational drug is administered> 
blood brain barrier: a naturally occurring barrier created by the modification of brain 
capillaries (as by reduction in fenestration and formation of tight cell-to-cell contacts) that 
prevents many substances from leaving the blood and crossing the capillary walls into the brain 
tissues 
bradykinin: a polypeptide hormone that is formed locally in injured tissue, acts in vasodilation 
of small arterioles, is considered to play a part in inflammatory processes, and is composed of a 
chain of nine amino acid residues 
cannabinoid: cannabinioids are a class of drugs that take their name from the cannabinoid 
botanical Cannabis sativa from which they were first isolated and include herbal preparations of 
cannabis as well as synthetic, semisynthetic, and extracted cannabinoid preparations (Aggarwal, 
2013) 
carcinogens: substances or agents that cause cancer 
cannabidiol: a crystalline diphenol C21H2s(OH)2 obtained from the hemp plant that is 
physiologically inactive but is rearranged by acids into THC 
catecholamines: any of various amines (as epinephrine, norepinephrine, and dopamine) that 
contain a dihydroxy benzene ring, that are derived from tyrosine, and that function as hormones 
or neurotransmitters or both 
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catalepsy: a trancelike state of consciousness (as that occurring in catatonic schizophrenia) that 
is marked by a loss of voluntary motion and a fixed posture in which the limbs remain in 
whatever position they are placed 
chemotherapy: the use of chemical agents in the treatment or control of disease or mental 
disorder 
clinical significance: refers to the practical or applied value or importance of the effect of an 
intervention and whether it makes a practical and noticeable difference in everyday life (i.e. 
improvement in quality of life and overall functioning) (Kazdin, 1999). 
combustion: a rapid chemical process that produces heat and light 
dependence, physical: a state of adaptation manifested by a drug class-specific withdrawal 
syndrome that can be produced by abrupt cessation, rapid dose reduction, decreasing blood level 
of the drug, and/or administration of an antagonist (Chou et al., 2009) 
dermis: the sensitive vascular inner mesodermic layer of the skin 
descending efferent pathways: pathways of the PNS that conduct nerve impulses away from 
the brain to the effector 
desensitization: to decrease a response (as of a cell receptor) progressively following prolonged 
exposure to a stimulus 
diversion: the intentional transfer of a controlled substance from legitimate distribution and 
dispensing channels (Chou et al., 2009) 
dorsal root neurons: the one of the two roots of a spinal nerve that passes posteriorly to the 
spinal cord separating the posterior and lateral funiculi and that consists of sensory fibers 
down regulation: the process of reducing or suppressing a response to a stimulus; specifically: 
reduction in a cellular response to a molecule (as insulin) due to a decrease in the number of 
receptors on the cell surface. 
emphysema: a condition of the lung that is marked by distension and eventual rupture of the 
alveoli with progressive loss of pulmonary elasticity, that is accompanied by shortness ofbreath 
with or without cough, and that may lead to impairment of heart action 
endocannabinoid: endogenous cannabinoids that are biosynthesized as needed, usually 
triggered by increased intracellular calcium ion concentrations. Have many roles including 
functioning as retrograde mediators passing information from postsynaptic to presynaptic 
neurons. Influence nociception, cardiovascular, respiratory and gastrointestinal functions (Rang 
et al., 2012) 
-_- _. 
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evidence-based medicine: the conscientious, explicit and judicious use of current best evidence 
in making decisions about the care of individual patients . The practice of evidence-based 
medicine means integrating individual clinical expertise with the best available external clinical 
evidence from systematic research. Evidence-based medicine does not mean "cook-book" 
medicine, or the unthinking use of guidelines. It does imply that evidence should be reasonably 
readily available in an easily understood and useable form (Bandolier, 2007) 
experimental study: a procedure carried out under controlled conditions in order to discover an 
unknown effect or law, to test or establish a hypothesis, or to illustrate a known law 
fibromyalgia: a chronic disorder characterized by widespread pain, tenderness, and stiffness of 
muscles and associated connective tissue structures that is typically accompanied by fatigue, 
headache, and sleep disturbances 
first past hepatic effect: the metabolism of orally administered drugs by gastrointestinal and 
hepatic enzymes, resulting in a significant reduction of the amount of unmetabolized drug 
reaching the systemic circulation (Medical Dictionary for the Health Professions and Nursing. 
(2012) 
glycine: a sweet crystalline nonessential amino acid C2H5N02 that is a neurotransmitter which 
induces inhibition of postsynaptic neurons, is obtained by hydrolysis of proteins 
half-life: the time that a living body requires to eliminate one half the quantity of an 
administered substance (as a radioisotope) through its normal channels of elimination 
histamine: a compound C5H9N3 especially of mammalian tissues that causes dilatation of 
capillaries, contraction of smooth muscle, and stimulation of gastric acid secretion, that is 
released during allergic reactions, and that is formed by decarboxylation of histidine 
hyperalgesia: increased sensitivity to pain or enhanced intensity of pain sensation 
lipogenesis: formation of fat in the living body especially when excessive or abnormal 
metabolism: the sum ofthe processes in the build-up and destruction of protoplasm; 
specifically : the chemical changes in living cells by which energy is provided for vital processes 
and activities and new material is assimilated 
nociceptor: a receptor for injurious or painful stimuli: a pain sense organ 
neurons: one of the cells that constitute nervous tissue, that have the property of transmitting 
and receiving nervous impulses, and that are composed of somewhat reddish or grayish 
protoplasm with a large nucleus containing a conspicuous nucleolus, irregular cytoplasmic 
granules, and cytoplasmic processes which are highly differentiated frequently as multiple 
dendrites or usually as solitary axons and which conduct impulses toward and away from the 
nerve cell body-called also nerve cell 
neurotransmitter: a substance (as norepinephrine or acetylcholine) that transmits nerve 
impulses across a synapse 
norepinephrine: a catecholamine C8H11N03 that is the chemical means of transmission across 
synapses in postganglionic neurons of the sympathetic nervous system and in some parts of the 
central nervous system, is a vasopressor hormone of the adrenal medulla, and is a precursor of 
epinephrine in its major biosynthetic pathway 
noxious stimuli: physically harmful or destructive to living beings 
nurse practitioner: an advanced practice nurse with a graduate education whose legislated 
scope of practice includes diagnostic and prescriptive authority (CRNBC, 2014b) 
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observational studies: in research about diseases or treatments, this refers to a study in which 
nature is allowed to take its course. Changes or differences in one characteristic (e.g. whether or 
not people received a specific treatment or intervention) are studied in relation to changes or 
differences in other(s) (e.g. whether or not they died), without the intervention of the 
investigator. There is a greater risk of selection bias than in experimental studies (Bandolier, 
2007) 
opioids (endogenous): any of a group of endogenous neural polypeptides (as an endorphin or 
enkephalin) that bind especially to opiate receptors and mimic some of the pharmacological 
properties of opiates-called also opioid peptide 
cytochrome P450 enzymes: haem proteins, comprising a large family of enzymes, but differ in 
reactions they catalyze. CYP 1, CYP2 and CYP3 are involved in drug metabolism of the liver 
(Rang et al. , 2012) 
pharmacodynamics: a branch of pharmacology dealing with the reactions between drugs and 
living systems 
pharmacokinetics: the study of the bodily absorption, distribution, metabolism, and excretion of 
drugs 
phospholipase A2 enzymes: an enzyme activated by the cannabinoids involved in prostaglandin 
synthesis and release (Evans, F ormukong & Evans, 1987) 
physical dependence: compulsive physiological need for and use of a habit-forming substance 
(as heroin, nicotine, or alcohol) characterized by tolerance and by well-defined physiological 
symptoms upon withdrawal 
phytocannabinoids: any plant-derived natural product capable of either directly interacting with 
cannabinoid receptors or sharing chemical similarity with cannabinoids or both and include THC 
and cannabidiol (Gertsch, Pertwee & DiMarzo, 2010) 
polymodal nociceptors: responding to several different forms of sensory stimulation (as heat, 
touch, and chemicals) <unmyelinated polymodal nociceptors> 
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post-herpetic neuralgia: pain that occurs along a nerve that persists for more than three months 
after the rash of herpes zoster (shingles) resolves (Venes, 2013). 
prostaglandins: any of various oxygenated unsaturated cyclic fatty acids of animals that are 
formed as cyclooxygenase metabolites especially from unsaturated fatty acids (as arachidonic 
acid) composed of a chain of 20 carbon atoms and that perform a variety of hormone like actions 
(as in controlling blood pressure or smooth muscle contraction) 
presynaptic: relating to, occurring in, or being part of a nerve cell by which a wave of excitation 
is conveyed to a synapse <presynaptic terminals><presynaptic inhibition><a presynaptic 
membrane> 
primary care: essential health care based on practical, scientifically sound and socially 
acceptable methods and technology made universally accessible to individuals and families 
throughtheir full participation and at a cost that the community and country can afford ... It is the 
first level ofcontact of individuals, the family and community with the national health system, 
bringing health careas close as possible to where people live and work, and constitutes the first 
element of a continuinghealth care process. 
psychological addiction: persistent compulsive use of a substance known by the user to be 
physically, psychologically, or socially harmful 
psychomotor behaviour: of or relating to motor action directly proceeding from mental activity 
psychosis: a serious mental disorder (as schizophrenia) characterized by defective or lost contact 
with reality often with hallucinations or delusions 
postsynaptic: relating to, occurring in, or being part of a nerve cell by which a wave of 
excitation is conveyed away from a synapse <postsynaptic dopamine receptors> 
schizophrenia: a psychotic disorder characterized by loss of contact with the environment, by 
noticeable deterioration in the level of functioning in everyday life, and by disintegration of 
personality expressed as disorder of feeling, thought (as in delusions), perception (as in 
hallucinations), and behavior 
sensitization: increased response of peripheral and central neurons to painful stimuli as a result 
of nociceptive insult and inflammation that follows the injury (Bauldoff, Burke, & LeMone, 
2011) 
serotonin (5-HTlA): a phenolic amine neurotransmitter C10H12N20 that is a powerful 
vasoconstrictor and is found especially in the brain, blood serum, and gastric mucous membrane 
of mammals- called also 5-HT, 5-hydroxytryptamine 
65 
somatic pain: somatic nociceptive pain arises from injury of tissue including skin and muscle, is 
well localized and varies in character (Bauldoff, Burke, & LeMone, 2011) 
sympathetic nervous system: the part of the autonomic nervous system that is concerned 
especially with preparing the body to react to situations of stress or emergency, that contains 
chiefly adrenergic fibers and tends to depress secretion, decrease the tone and contractility of 
smooth muscle, increase heart rate, and that consists essentially of preganglionic fibers arising in 
the thoracic and upper lumbar parts of the spinal cord and passing through delicate white rami 
communicates to ganglia located in a pair of sympathetic chains situated one on each side of the 
spinal column or to more peripheral ganglia or ganglionated plexuses and postganglionic fibers 
passing typically through gray rami communicates to spinal nerves with which they are 
distributed to various end organs 
synthetic: of, relating to, or produced by chemical or biochemical synthesis; especially: 
produced artificially <synthetic drugs> 
terminal half life: or biological half-life, the time that a living body requires to eliminate one 
half the quantity of an administered substance (as a radioisotope) through its normal channels of 
elimination 
thalamus: the largest subdivision of the diencephalon that consists chiefly of an ovoid mass of 
nuclei in each lateral wall of the third ventricle and serves to relay impulses and especially 
sensory impulses to and from the cerebral cortex 
tolerance: the capacity of the body to endure or become less responsive to a substance (as a 
drug) or a physiological insult especially with repeated use or exposure <developed a tolerance 
to painkillers> 
toxicity: refers to adverse effects that can be caused by the principal pharmacological action of 
the drug (bleeding with anticoagulant) or unrelated to the effects of the pharmacological action 
(liver damage from paracetamol) (Rang et al. 2012) 
transient receptor potential channels (TRPs): ion channels present on sensory neurons that are 
activated by thermal stimuli and chemical agents. Capsaicin, the substance in chili peppers, 
activates TRPV1 , resulting in pain and heat (Rang et al. 2012) 
tryptophan: a crystalline essential amino acid c,,H,2N202 that is widely distributed in proteins 
visceral pain: visceral nociceptive pain occurs with stimulation of stretch receptors in visceral 
tissue typically located in organs; the pain is poorly localized, deep, dull and cramping (Bauldoff 
et al., 2011) 
xenobiotic: a chemical compound (as a drug, pesticide, or carcinogen) that is foreign to a living 
orgamsm 
_. 
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Appendix A 
WHO Guidelines for Rational Prescribing (de Vries et al., 1994) 
Step 1: Define the client's problem . Perform history, physical and evaluate 
labs/diagnostic tests 
• Establish diagnosis 
Step 2: Specify the therapeutic objective • Determine what you and the client want 
to accomplish with the medication 
Step 3: Verify suitability of the • What is the efficacy of the drug on 
p( ersonal)-drug therapeutic objective . Safety of drug: adverse and toxic 
effects, safety margins, 
contraindications (i.e. in high risk 
group) and drug-interactions specific 
to client 
• Suitability of dosing, formulation to 
age,mentalstatus,concurrent 
medications, food interactions, 
co morbidities 
• Cost of drug to client 
Step 4: Write a prescription • Include strength, dose, route, total 
amount to be dispensed 
Step 5: Give information, instructions and • Give information on drug, 
warnings administration, and warnings 
Step 6: Monitor treatment • Establish regular follow-up visits to 
determine if medication meeting 
therapeutic objective 
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Appendix B 
Initial Search: "cannabis" "medical 110 
Google and marijuana" 
Google Scholar "neuropathic pain" 
2009-2014 
~~ 
Database Search terms Result Hand Search Search Result 
(MeSH unless terms 
otherwise Pain Research "cannabis" I 
written with " and AND 
term") Man'!Kement "neuropathic 
Cochrane "Cannab*" OR 80 The Journal pain" 41 
Reviews "THC"OR of Pain and 
"marijuana" PAIN 
AND Journal 
"neuralgia" OR National 2 
"neuropathic Guidelines 
pain" OR Clearinghouse 
"neuropathy" Health "neuropathic II 
CINAHL cannabis OR 24 Canada pain" 
Medline Ovid medical 15 Information 
Medline full marijuana AND 10 for Health 
text neuralgia OR Care 
neuropathy Professionals: 
Pub Med cannabis OR 31 Cannabis 
cannabinoids (marijuana, 
OR medical marijuana) 
marijuana OR and 
"THC" AND cannabinoids 
neuralgia Websites Search Result 
Psychlnfo cannabis OR 6 Terms 
cannabinoids Health "cannabis" 4 
OR marijuana Canada OR "medical 
AND neuralgia Gov't of marijuana" 3 
OR neuropathic 
Canada AND 
pain 
Canadian "neuropathic 3 
Biomedical ref "cannabis" 18 
Medical pain" 
AND Assoc . 
"neuropathy" 
American I 
Longwoods "cannabis", I Psychiatric 
"marijuana" 
Assoc. 
~ ~ 
Total Articles = 360 
(see Figure I) 
Appendix C 
Table 1: Study Quality Checklist 
Reportin2 
1. Is the hypothesis/aim/objective of the 6. Are the main findings of the study 
study clearly described? clearly described? 
Yes-1 No-0 Yes-1 No-0 
2. Are the main outcomes to be measured 
clearly described in the Introduction or 
Methods section? 
Yes-1 No-0 
3. Are the characteristics of the patients 
included in the study clearly described ? 
Yes -1 No- 0 
4. Are the interventions of interest clearly 
described? 
Yes-1 No-0 
5. Are the distributions of principal 
confounders in each group of subjects to be 
compared clearly described? 
Yes- 2 Partially- 1 No- 0 
7. Does the study provide estimates of the 
random variability in the data for the main 
outcomes? 
Yes -1 No- 0 
8. Have all important adverse events that 
may be a consequence of the intervention 
been reported? 
Yes -1 No- 0 
9. Have the characteristics of patients lost 
to follow-up been described? 
Yes-1 No-0 
10. Have actual probability values been 
reported( e.g. 0.035 rather than <0.05) for 
the main outcomes except where the 
probability value is less than 0.001? 
Yes-1 No-0 
External Validity 
11. Were the subjects asked to participate 13. Were the staff, places, and facilities 
in the study representative of the entire where the patients were treated, 
population from which they were representative of the treatment the majority 
recruited? of patients receive? 
Yes- 1 No- 0 Unable to determine- 0 Yes- 1 No- 0 Unable to determine- 0 
12. Were those subjects who were prepared 
to participate representative of the entire 
population from which they were 
recruited? 
Yes- 1 No- 0 Unable to determine- 0 
Internal Validity - Bias 
14. Was an attempt made to blind study 18. Were the statistical tests used to assess 
subjects to the intervention they have the main outcomes appropriate? 
received? Yes- 1 No- 0 Unable to determine- 0 
Yes- 1 No- 0 Unable to determine- 0 
15. Was an attempt made to blind those 
measuring the main outcomes of the 
intervention? 
Yes- 1 No- 0 Unable to determine- 0 
16. If any of the results of the study were 
based on "data dredging", was this made 
clear? 
19. Was compliance with the intervention/s 
reliable? 
Yes- 1 No- 0 Unable to determine- 0 
20. Were the main outcome measures used 
accurate (valid and reliable)? 
Yes- 1 No- 0 Unable to determine- 0 
78 
Yes- 1 No- 0 Unable to determine- 0 
17. In trials and cohort studies, do the 
analyses adjust for different lengths of 
follow-up of patients, or in case-control 
studies, is the time period between the 
intervention and outcome the same for 
cases and controls ? 
Yes- 1 No- 0 Unable to determine- 0 
Internal Validity- Confounding (Selection Bias) 
21. Were the patients in different 24. Was the randomised intervention 
intervention groups (trials and cohort assignment concealed from both patients 
studies) or were the cases and controls and health care staff until recruitment was 
(case-control studies) recruited from the complete and irrevocable? 
same population? Yes- 1 No- 0 Unable to determine- 0 
Yes- 1 No- 0 Unable to Determine- 0 
22. Were study subjects in different 
intervention groups (trials and cohort 
studies) or were the cases and controls 
(case-control studies) recruited over the 
same period of time? 
Yes- 1 No - 0 Unable to determine - 0 
25 . Was there adequate adjustment for 
confounding in the analyses from which 
the main findings were drawn? 
Yes- 1 No- 0 Unable to determine- 0 
23 . Were study subjects randomised to 26. Were losses of patients to follow-up 
intervention groups? taken into account? 
Yes- 1 No - 0 Unable to determine- 0 Yes- 1 No- 0 Unable to determine- 0 
Power 
27. Did the study have sufficient power to 
detect a clinically important effect where 
the probability value for a difference being 
due to chance is less than 5%? (modified) 
Yes-1 No- 0 
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Note. From "The feas ibili ty of creating a checkli st for the assessment of the methodological quali ty both of 
randomized and non-randomized studies of health care interventions," by S. H. Downs & N. Black, 1998. Journal of 
Epidemiology and Community Health , 52(6), 377-384. Reprinted with permission. 
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T bl 2 St d 0 t a e u lY u comes 
Research Methodology Quality Analysis/ Conclusions Implications for Implications 
Question Rating Results future research for practice 
# / 28 
(Downs 
&Black 
,1998) 
To determine the Prospective 25 SC pain by 34% vs -SC was - studies using -NNTand 
efficacy of smoked randomized 17% placebo (p =0.03) more people who have pain 
cannabis (SC) on placebo-controlled 52% > 30% pain effective in not used cannabis reduction not 
HIV -assoc. sensory trial reduction vs 24% H!V-SN vs before better than 
neuropathy (HIV -SN) placebo (p =0.04) placebo -studies on current 
THC: 0% vs 3.56% Hyperalgesia 34% SC -Results are smoked or oral treatments 
,-... vs II % placebo (p0.05) consistent cannabis for -possible 3'• r-= N=55 (n=SO with pre- neuropathy not line agent = N finished) no withdrawal from AlE clinical pain associated with -use for 
'-" 
-; model HJV patients with NNT 3.6 studies with hyperalgesia .... 
~ systemic -caution with 
"' miTT method of cannabinoid cannabis 5 analysis s naive clients 01 .. -acceptable ~ 
< safety 
margin 
-no apparent 
reaction 
with other 
medications 
taken 
Does cannabis Open-label clinical 22 Pain by 27% from vc -further The 
~ augment the trial, nonplacebo baseline after vaporized augments controlled studies combination - analgesic effects of controlled cannabis (95% Cl 9,46) the analgesic of the synergistic may allow -= opioids? No withdrawal from effects of interaction for opioid M ._, 
N=24 (n=21 AlE opioids between treatment at 
-; finished) without cannabinoids and lower doses ..... 
"' anxiety/depression significantly opioids with fewer "' Vaporized cannabis altering are warranted. side effects. E 
OS (VC) 3.56% per-protocol method plasma -evaluation of -caution for ... 
..Q analysis opioid other forms of use in 
< levels. cannabinoids cannabis 
naive patients 
Assess the safety and Randomizeddouble 27 SC of 4.28 more points -SC was -larger, longer -SC could be 
efficacy of smoked -blind, placebo on VAS vs placebo (p superior to term studies to offered to 
cannabis vs placebo controlled 0.009). placebo in determine if MS patients 
in pts with MS (tx- crossover design PASAT 6.981 SC vs pain lower doses still with 
resistant) spasticity placebo (p 0.003) reduction work with less refractory 
THC 0 VS 4% n=S w id because of ale -wid cognitive effects spasticity and 
N' because of -people with minor pain -= N=37(n=30 Intention-to-treat cognitive more intense -expect t!. finished study) analysis effects baseline pain cognitive 
-; -no serious -to do study on effects 
..... effects other patient -can ' t "' E -SC does populations generalize to 
~ effect (mentally ill, all patients ~ 
=s cognition major medical -caution with 
I (though conditions) cannabis >. 
"' clients still -long term naive patients ... ~ within range cognitive effects -caution for u 
for their age use in 
and patients that 
education) need mental 
alertness for 
their work 
(driving et) 
Is it effective for Subanalysis of a 20 MJ rated as more MJwas -Need larger -cannot draw 
symptom relief in RCT effective for relieving rated more sample size conclusions 
-; HIV? NeP effective -basis for future for use in 
..... ~ Subanalysis N=768 Not stat signif. than other clinical trial practice other 
"' ~ compared MJ to other meds for -effect of MJ on than reported "'= "'= meds for neuropathy anxiety/depression NeP plasma levels of positive ~t! 
~ other meds correlations 
u with MJ use 
forHIV 
svmptoms 
Research 
Question 
To ascertain a safe, 
clinically useful and 
efficacious dosing 
range for smoked 
medicinal cannabis as 
a short term analgesic 
in the tx of refractory 
NeP in HIV DSPN 
Assessed the 
effect of SC on NeP 
and experimentally-
induced pain in 
individuals with 
painful neuropathy 
due to HIY or ARYs 
What is the effect on 
pain for clients using 
MM under the 
program? 
Used a human exp, 
pain model and a 
dose-response design 
to evaluate the effects 
of SC on acute 
nociceptive 
processing and the 
facilitated pain state 
Methodology 
Phase II, double-
blind, placebo-
controlled, 
crossover trial 
THC 1-8% (self-
titrated dosing) 
N=34 (n=28 
finished) 
Open-label pilot 
inpatient study 
conducted over 9 
days 
THC 3.56% 
N= I6 
Descriptive survey 
on case series 
11-point pain rating 
scale 
I-5g/day 
N=30 
randomized, 
double-blinded, 
placebo-controlled, 
crossover trial 
THC 2,4, 8% 
N = l9 (n=l5 
completed) 
Quality 
Rating 
#/28 
(Downs 
&Black 
,1998) 
27 
13 
18 
24 
Analysis/ 
Results 
Cannabis >placebo pain 
relief DDS pain 
intensity scale (p 0.0 16) 
46% had 30% reduction 
in pain compared to 
placebo 
0.46 (95%CJ 
0.28, 0.65) VS 0.18 
(95%Cl 0.03, 0.32), p = 
0.043). 
anxiety/depression 
NNT= 3.5 
ITT analysis 
> 30% reduction in 
baseline pain for 10/16 
clients 
> 30% reduction of 
hyperalgesia for 14116 
patients 
No Cl or P value 
calculated 
-93% reported reduction 
in pain 6110 points 
{>30%) 
-use of other OTC meds 
anxiety/depression 
Low dose no effect 
Medium dose dec. pain 
(SS compared to 
placebo delayed) 
High dose pain 
No effect on 
hyperalgesia 
Per-protocol method of 
analysis 
Conclusions 
-SC did pain 
compared to 
placebo 
-there were 
2 subjects 
with S/E that 
had them 
drop out 
(psychosis 
and cough) 
-no change 
on CD4 or 
viral loads 
Smoked 
THC 
decreased 
pain and 
hyperalgesia 
in HIY-
associated 
neuropathy 
There is 
evidence 
thatMM 
may be an 
alternative 
for 
refractory 
pain 
Medium 
dose 
relieved pain 
without 
adverse 
effects 
-narrow 
therapeutic 
window for 
pain 
Implications for 
future research 
-need longer term 
study to 
determine if SIE 
will be more 
pronounced 
-can it be applied 
to those with 
other types of 
NeP 
A 50 subject 7-
day randomized 
placebo-
controlled trial 
has been initiated 
in an attempt to 
confirm these 
preliminary 
findings. 
Need to have 
larger, placebo 
controlled studies 
to determine 
safety and effect 
of use with other 
medications 
-short term, small 
sample size 
-evaluate other 
compounds in 
cannabis that may 
have contributed 
to increase pain at 
higher doses 
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Implications 
for practice 
-smoking is 
effective but 
not for 
everyone -
some cannot 
tolerate, 
assoc, with 
COPD 
-may be good 
for those with 
refractory 
pain 
-can be used 
with other 
drugs with no 
concern for 
interactions 
-those with 
lung 
conditions or 
mental health 
conditions 
may not be 
candidates 
-again no 
substance use 
included 
-may be used 
as adjunct for 
refractory 
NeP forHIV 
clients 
-caution with 
use in 
cannabis 
naive patients 
-use in clients 
on other 
medications 
-consider use 
for clients 
with 
refractory 
NeP 
-concerns 
about 
smoking as 
delivery 
system 
-they did not 
advocate use 
of cannabis 
for pain at 
this time due 
to abuse 
potential, 
tolerance, 
efficacy and 
safety issues 
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Research Methodology Quality Analysis/ Conclusions Implications for Implications 
Question Rating Results future research for practice 
# I 28 
(Downs 
&Black 
,I998) 
safety and efficacy of Randomizeddouble 22 9,4 vs O%(p=0.023 , Cl -SC -future trial to use -use for 
smoked cannabis in -blind, placebo- 0,02-1.4) improved vaporizer instead clients as 
outpatients with controlled, four- pain, sleep, of smoke adjuvant 
s chronic NeP. period crossover No serious AlE anxiety -need higher therapy - design expected, AlE with -one potencies and -not for use 0 
!::!. THC dose withdrawal flex ible dosing with 
-; THC 0, 2.5, 6, d/t pain. strategies cardiac/pulm. 
..... 9.4% No difference in -determine effect Disease 
"' sleep/quality of life of cannabis on -okay for usc "' ... N=23 anxiety/depression other medication with clients 
" ~ (n =2 l fi nished) plasma levels who take 
other 
Per-protocol analysis medications 
To evaluate the RCT crossover trial 25 Allodynia (n =23) no SS Cannabis Larger, longer Low dose 
.-. analgesic efficacy of of cannabis (high, with di fferent was studies may help QO 
0 smoking cannabis for low, no doses) concentrations effective for Alternative to with less 
0 
!::!. NcP of cannabis (p =.40) or NeP smoking diversion 
-; N=38 cumulative dose {p= .29) Low dose risk, for 
..... (n =33 0% worked as clients with 
"' n=36 3.5% well as high jobs that ..., 
"' n=34 7% fin ished) Per-protocol analysis dose with require ..!l less cognition ~ psychoactive intact 
effects 
evaluating the double-blind, 24 30% pain for low/mod -present -larger longer - low dose, 
analgesic placebo-controlled, doses study adds studies nonsmoke 
.-. efficacy of low dose crossover study -no dropouts due to SIE to growing regulated/standar delivery ...., THCwith -tolerated SIE with good literature of d plant usc to be system -0 vaporization cannabis 1.29%THC pain relief cannabis use able to quantify worked may 
!::!. refractory NeP 3.53% THC -no sig diffbetwecn forNeP dosing make it easier 
-; -vaporize not smoke mcd and low dose -vaporizing -to do studies for 
..... N=39 (n=38 0%, low dose with clients tbat prescribers "' ..., n=37 1.29%, NNT: 3.2 (low); 2.9 worked well were excluded -can only 
"' ..!l n=36 3.53% (mcd) -quantitati ve (mentally ill, generalize to 
~ fi nished) prescribing substance use, study 
Per-protocol analysis not feasible severe medical demographic 
at present illness) s 
time 
To investigate H!V- anonymous cross- 21 90% reported -cannabis is -for use in other -for use in 
.-. symptom sectional question- improvement ofNcP used by client clients with on 
0 management with naire study. (n=53) (p=O) many H!V demographics and HIV-
0 
!::!. cannabis clients for illnesses associated 
-; Varied forms of anxiety/depression symptom -clinical trials symptoms 
Ql deli very 
control evaluating -use in 
"' 
-effective cannabis on Ne P patients with 
t>ll N= l43 used for NeP -longer study NeP ~ ·.:: cannabis for evaluating -use in clients 
0 symptom mx (n =6 l cannabis on HIV taking other 
Q 
~ nerve pain) viral loads/CD4 medications 
